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Inborn errors of metabolism (IEM) are caused by biochemical inbalance in the 
organism resulting from pathogenic mutations. Many of these present in neo-
natal age or in infancy, but the number of diseases diagnosed in childhood and 
the teen years is increasing, including congenital metabolic disorders causing 
health problems in adulthood (Saudubray 1995).   
Historically, the hypothesis of “chemical physiology and pathology” in man 
was first presented by Sir Archibald Garrod in 1908 in his four Croonian 
lectures (Garrod 1908). He was the first to use the term “inborn errors of meta-
bolism” and to apply Mendel’s law of segregation to humans, including the 
description of recessive inheritance while pointing out the importance of 
consanguinity. Although not appreciated during his lifetime, during the 20th 
century Garrod’s ideas accumulated supporting scientific evidence, and each of 
his chapter has acquired its own genomic locus, a cloned gene, a repertoire of 
annotated phenotype-modifying alleles, a gene product with known structure 
and function and altered function in Mendelian variant (Scriver 2008). 
The first systematic review in the field of IEM in Estonia was published in 
1996 by Õunap et al. (Õunap et al., 1996). This work established the incidence 
of phenylketonuria (PKU) and made possible the development of a newborn 
screening program for the early detection of PKU in children. In 1998 it was 
shown that the incidence of PKU in Estonia identified during retrospective 
studies is lower than the incidence identified prospectively during newborn 
screening (NBS) (Õunap et al., 1998). Early detection of PKU allows for 
presymptomatic treatment of patients, and the development of mental retar-
dation is avoided. In 2012 the Estonian guidelines for PKU treatment were 
published (Uudelepp et al., 2012). 
Due to the non-specific clinical picture characteristic of most IEMs, the 
diagnostics is largely dependant on the availability of specific laboratory in-
vestigations. In 2007, when this project was initiated, the following analytical 
methods were available in the diagnosis of IEM in Estonia: simple urine 
screening tests, high-performance liquid chromatography (HPLC) of amino 
acids, and gas chromatography/mass spectrometry (GC/MS) of organic acids. In 
addition, urinary creatine and guanidinoacetate was measured for the diagnosis 
of defects of creatine metabolism, and quantitative analysis of very long chain 
fatty acids is available for the diagnosis of peroxisomal diseases (GC/MS 
method). Lactate, ammonia, homocysteine and total sialotransferrine measure-
ment was used in the primary screening of related diseases. There were, how-
ever, several groups of IEMs where specific analyses were not available in 
Estonia, and these were performed in other European laboratories in the case of 
clinical suspicion. These included energy deficiency disorders such as fatty acid 
β-oxidation defects (FAOD) and mitochondrial disorders (MD).  
Early identification of FAOD is clinically important, as the clinical outcome 
in those disorders is generally favourable, but they are related with significant 
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mortality if they remain undiagnosed (Sim et al., 2002). The first diagnostic test 
of FAOD to become available in Estonia was molecular genetic testing for the 
common mutations in genes responsible for medium-chain acyl-CoA dehydro-
genase (MCAD) deficiency and long-chain acyl-CoA dehydrogenase (LCHAD) 
deficiency. Lilleväli et al have shown that carrier frequency for the mutation 
c.985A>G (p.K329E) in the ACADM gene responsible for the MCAD defi-
ciency (MCADD) is 1:220 in Estonia, and the frequency of possibly affected 
homozygotes is 1:193,000 (Lilleväli et al., 2000), but no MCADD patients were 
known until 2007. LCHAD deficiency (LCHADD) was diagnosed retrospec-
tively in one family. Mutational analysis in FAOD has limited informativeness, 
as common mutations are not entirely responsible for the development of the 
disease. In addition, the clinical phenotype of MCADD and LCHADD overlaps 
to a great extent, and therefore the detection of the mutations related with both 
forms of the disease was generally necessary and was time-consuming and 
expensive. Acylcarnitine analysis using tandem mass spectrometry (MS/MS) in 
bodily fluids as developed by Millington et al in 1989 has been shown to be 
highly informative in the diagnosis of FAOD, and allows simultaneous and 
quick detection of all FAODs from one sample (Millington et al., 1989). It has 
been successfully applied in expanded NBS, allowing presymptomatic testing 
of >20 congenital conditions (Lindner et al., 2011; Lindner et al., 2010; Schulze 
et al., 2003; Wilcken et al., 2003).  
MD are probably one of the most common IEMs, and have an estimated 
frequency of 1:5000–10,000 (Skladal et al., 2003). The diagnosis of these dis-
orders is, however, complex, as there is no single test with sufficient accuracy to 
prove or exclude the presence of a mitochondrial disorder in the patient. MD 
presenting in childhood in Estonia has previously been diagnosed in only one 
patient with Leigh syndrome (LS) caused by respiratory chain complex I 
deficiency due to a mutation in the mitochondrial ND3 gene.  
The “gold standard” in diagnostics is morphological and enzymatic investi-
gations performed on muscular tissue, but as muscular biopsy is invasive, time-
consuming and some tests are not available in Estonia, the careful pre-selection 
of patients suggestive of a MD is essential. Therefore in 2004 we developed a 
diagnostic algorithm for MD which takes into account our local diagnostic 
possibilities and medical organization.   
In order to improve the diagnostics of IEM in Estonia, we undertook this 
study with the following aims: to introduce acylcarnitine analysis by MS/MS 
into the clinical diagnostics of FAOD and to evaluate the effectiveness of a 
diagnostic algorithm for MD in Estonia and to establish the live-birth pre-
valence of those disorders in our population. During our study we also 






2. LITERATURE REVIEW 
2.1. An overview of metabolic diseases 
The basic biochemical lesions in monogenic disorders involve defects in a wide 
variety of proteins, mostly enzymes, receptors, transport proteins, peptide hor-
mones, immunoglobulins, collagens and coagulation factors. The vast majority 
of IEMs involve abnormalities in enzymes and transport proteins, and the basic 
biochemical lesion usually affects either one metabolic pathway common to a 
large number of cells or several organs or is restricted to one organ but gives 
rise to humoral and systemic consequences. According Saudubray and Char-
pentier, IEMs can be subdivided into 3 groups from the pathophysiological 
perspective (Saudubray 1995). 
 Group 1 – storage type. This group includes diseases that disrupt the 
synthesis or catabolism of complex molecules, leading to storage phenomena 
and chronic toxicity. Clinical symptoms are permanent, progressive, indepen-
dent of intercurrent events and unrelated to food intake. Lysosomal storage 
disorders, peroxisomal biogenesis disorders, congenital glycosylation defects 
and cholesterol biosynthesis defects belong to this group. The diagnosis of this 
group relies largely on measurement of the activities of specific enzymes in 
tissues, but the first line tests used in the selective screening of the diseases of 
this group are the measurement of serum very long chain fatty acids (peroxi-
somal biogenesis defects) or serum cholesterol precursors (cholesterol bio-
synthesis defects) or urinary excretion of glycosaminoglycans and oligosaccha-
rides (lysosomal storage disorders). Isoelectric focussing of serum transferrins 
is indicated in suspicion of congenital glycosylation defects.  
 Group 2 – intoxication type. This group includes diseases where the 
accumulation of substrate of the deficient enzyme reaction (or transporter) will 
result in toxicity and disease. The accumulating substrates may be metabolised 
via alternative pathways that may yield further toxic compounds that normally 
occur at low concentrations, if present at all. This metabolic disturbance may 
cause acute toxicity or chronic toxicity in the long term. All of the conditions in 
this group present clinical similarities, including a symptom-free interval, 
clinical signs of intoxication, which may be either acute (vomiting, lethargy, 
coma, liver failure, or thromboembolic complications) or chronic (progressive 
psychomotor retardation) and recurrent metabolic disturbances (acidosis, 
ketosis, and/or hyperammonemia). This group includes most of the amino-
acidopathies, most of the organic acidurias, urea cycle defects (UCD) and sugar 
intolerances. Biochemical diagnosis is easy and relies mostly on plasma and 
urine amino acid or organic acid chromatography. Treatment of these disorders 
requires removal of the toxic compounds through special diets, exchange 
transfusion or hemodialysis.  
 Group 3 – energy deficiency type. Compromised mitochondrial energy 
production at the levels of fatty acid oxidation (FAO), tricarboxylic acid cycle 
and respiratory chain enzymes fall into this group. Energy utilisation disorders 
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such as disorders of glyconeogenesis and glycogen storage diseases also belong 
to this group. These diseases present an overlapping clinical spectrum that 
sometimes results from both the accumulation of toxic compounds and deficient 
energy production. These disorders predominately affect organs with great 
energy consumption (brain, muscle, liver). Symptoms common to this group 
include hypoglycaemia, lactic acidosis, severe generalised hypotonia, myo-
pathy, cardiomyopathy, failure to thrive, cardiac failure, circulatory collapse, 
sudden infant death syndrome (SIDS), and malformations (the latter suggesting 
that the abnormal processes affect the foetal energy pathways (Illsinger and Das 
2010). The extreme clinical diversity of these disorders illustrates the ubiquitous 
role of energy processes at every age and in every organ. Treatment of these 
disorders would generally require adequate energy replacement. 
 More than 700 different IEMs are known (Illsinger and Das 2010). These are 
individually rare, but as a group their incidence is significant – approximately 
1:2500 live births (Applegarth et al., 2000). The overview of the more frequent 
disorders among Caucasians and their known frequencies among Estonians are 
given in table 1. 
 
 
Table 1. More frequent IEMs presenting in childhood.  
 
Disease or group Prevalence among 
Caucasians 
Prevalence in Estonia 
PKU  1:10,000 (Mathias and 
Bickel 1986) 
1:6010 (Õunap et al., 
1998; Õunap 1999) 
Classical galactosaemia  1:23,000 – 1:44,000 
(Bosch 2006; 
Schweitzer-Krantz 2003) 
1:19,700 (Õunap et al., 
2010) 
Urea cycle defects 1:8000 – 1:39,000 
(Braissant 2010; 
Keskinen et al., 2008) 
Unknown 
Mucopolysaccharidoses (MPS) 1:25,000 (Nelson 1997; 
Poorthuis et al., 1999) 
1:24,687 (Krabbi et al., 
2012) 
 MCADD 1:15,000 (Lindner et al., 
2010) 
1:193,000 (Lilleväli et 
al., 2000) 
 LCHADD  1:250,000 (Lindner et al., 
2010) 
1:94,864 (this study)  
Publication I 
MD 1:5000 –  1:10,000 
(Skladal et al., 2003)  






2.2. Fatty acid oxidation defects 
2.2.1. An introduction to FAO 
Fatty acids (FA) represent a major source of energy in man, providing up to 
80% of total energy requirements during fasting (Zschocke and Hoffmann 
2011). FAO is a key metabolic pathway for energy homeostasis in organs such 
as the liver, heart and skeletal muscle. It becomes essential during fasting, when 
glucose supply becomes limited and most tissues use FA directly to create 
energy. Furthermore, FA are converted into ketone bodies in the liver and can 
subsequently function as an additional energy source that is used by all tissues, 
including the brain. 
 
Classification of fatty acids:  
FA are classified:  a. on the basis of chain length (table 2); 
b. on the basis of chemical structure: FA without 
double bonds are saturated, and FA without double 
bonds are unsaturated. 
 
 
Table 2. Classification of FA on the basis of chain length. 
 
FA No. of carbons 
Short-chain fatty acids <6 
Medium-chain fatty acids (MC-FA) 6–12 
Long-chain fatty acids (LC-FA) 14–20 
Very long chain fatty acids >22 
 
     
FAO was discovered by Georg Franz Knoop, whose experiments led to the con-
clusion that the metabolism of FA proceeds through the successive removal of two 
carbon fragments, and postulated that the oxidation takes place on the β-carbon 
atom. Knoop published the results of his experiments in 1904. In 1955 Irving B. 
Fritz discovered the role of carnitine in FAO (Houten and Wanders 2010).  
 Palmitoyltransferase I deficiency was the first defect in an FAO pathway that 
was clinically described in a patient with familial recurrent myoglobinuria in 
1973 by DiMauro and DiMauro (1973). Carnitine deficiency in skeletal muscle 
in association with lipid storage myopathy was first described in the same year 
(Engel and Angelini 1973). Karpati et al described the syndrome of systemic 
carnitine deficiency in a patient with recurrent hepatitis and cerebral dys-
function and underdeveloped musculature with impaired ketogenesis and no 
sign of oxidation LC-FA (Karpati et al., 1975). In 1976 Gregersen et al 
described the first patient with MCADD in a patient with unexplained episodes 
of lethargy and consciousness with elevated urinary excretion of suberylglycine 
and C6-C10 decarboxylic acids. Long-chain acyl coenzymeA dehydrogenase 
(LCAD) deficiency and LCHADD were described in 1985 and 1989 respec-
tively (Hale et al., 1985; Wanders et al., 1989).  
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2.2.2. The metabolism of FA 
During fasting or prolonged exercise, LC-FA stored as triglycerides in fat tissue 
are released by lipases. Free fatty acids (FFA) move into the blood stream and 
are transported there by serum albumin. In the plasma membrane FA are trans-
located into cytosol by fatty acid transport proteins, which are transmembrane 
proteins that possess acyl-CoA synthetase activity (Houten and Wanders 2010).  
The carnitine shuttle: The inner mitochondrial membrane is not permeable 
to LC-FA, which form the major part of dietary fatty acids. They are transported 
into the mitochondria via the carnitine shuttle, which consists of three enzymes 
(carnitine palmitoyltransferase 1 (CPT1), carnitine acylcarnitine translocase 
(CACT, SLC25A20), carnitine palmitoyltransferase 2 (CPT2)) and a small, 
soluble molecule, carnitine, to transport FA as their long-chain fatty acylcarni-
tine esters. CPT1 converts acyl-CoA into an acylcarnitine. Subsequently CACT 
exchanges acylcarnitine for free carnitine inside the mitochondria. Finally CPT2 
reconverts the acylcarnitines into their CoA esters, which then enter β-
oxidation. 
β-oxidation: After transport across the plasma membrane, FA are activated 
to acyl-CoAs at the cytosolic site. β-oxidation takes place in mitochondria and 
consists of a series of cycles, each of which shortens the fatty acids by 2 carbon 
atoms. Each cycle consists of 4 enzymatic reactions. First acyl-CoA is de-
hydrogenated to a trans-2-enoyl-CoA, which is hydrated to form L-3-hydroxy-
acyl-CoA in the next step. The third reaction in this cycle is dehydrogenation to 
form 3-keto-acyl-CoA. Finally, thiolytic cleavage produces an acyl-CoA 
shortened by two carbons and acetyl-CoA. Shortened acyl-CoA enters into the 
new cycle and acetyl-CoA enters into the citric acid (Krebs) cycle. In addition 
to acyl-CoA and acetyl-CoA, each cycle yields one nicotinamide adenine 
dinucleotide (NADH) and one flavin adenine dinucleotide (FADH2), which are 
later reoxydized in the mitochondrial respiratory chain. The electron transfer 
from FAD dependant dehydrogenases is mediated by electron transfer flavo-
protein (ETF). The characterisation of β-oxidation is schematically illustrated in 
figure 1. 
 Long chain acyl-CoAs are metabolised by membrane-bound enzymes very-
long-chain acyl-CoA dehydrogenase (VLCAD) and mitochondrial trifunctional 
protein (MTP). MTP has hydratase, LCHAD and thiolase activity (LCKAT). 
After 2–3 FAO cycles using these enzymes, the resulting medium and short 
chain acyl-CoAs are metabolised in the mitochondrial matrix via a cycle that 






Figure 1: β-oxidation in the mitochondria.  
 
 
Inherited deficiencies of most of the enzymes involved in carnitine transport, 
the carnitine shuttle and β-oxidation are known (table 3). 
 Regulation of FAO and substrate use in energy homeostasis: The reci-
procal relationship between the oxidation of FA and glucose is known as the 
glucose-fatty acid or Randle cycle. This cycle explains the mechanisms through 
which glucose is spared for usage in brain tissue. In the fasted state, activation 
of lipolysis provides tissues with FA. In the liver, β-oxidation of FA fulfils the 
local energy needs and may lead to ketogenesis. Ketone bodies are prefe-
rentially oxidized in extrahepatic tissues. By inhibiting glucose oxidation, FA 
and ketone bodies contribute to a glucose-sparing effect, which is an essential 
survival mechanism for the brain during starvation (Hue and Taegtmeyer 2009). 
Substrate availability is regulated by hormonal and metabolic factors. Insulin 
increases glucose transport and inhibits lipolysis, which decreases substrate 
availability for FAO. The release of FFA into the circulatory system is, how-
ever, increased by adrenalin, noradrenaline, glucagon and adrenocorticotropic 
hormone, which all induce lipolysis. 
 CPT1 activity is regulated by malony-CoA. As the level of adenosine 
triphosphate (ATP) decreases and the level of adenosine monophosphate (AMP) 
increases, the AMP-activated protein kinase (AMPK) is activated. Activated 
AMPK leads to acetyl-CoA decarboxylase inactivation, possibly together with 
malonyl-CoA decarboxylase activation, which decreases malonyl-CoA con-
centration and hence favours FAO (Hue and Taegtmeyer 2009). 
 Additionally, pyruvate dehydrogenase (PDH) catalyses the oxidative de-
carboxylation of pyruvate to acetyl-CoA and links glycolysis with oxidative 
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metabolism. Metabolites can also affect the trancriptional regulation of genes 
involved in metabolism (Houten and Wanders 2010). 
 
 
Table 3. Inherited deficiencies of the enzymes involved in carnitine transport, the carni-
tine shuttle and β-oxidation, the genes responsible and the OMIM numbers of clinical 
phenotypes. 
 











CPT2 CPT2 deficiency CPT2 608836 (lethal 
neonatal) 
600648 (infantile) 
255110 (late onset 
VLCAD VLCAD deficiency ACADVL 201475 
MTP LCHAD (MTP β-subunit) HADHA 600890 
LCKAT (MTP-β-subunit) HADHB 609015 
LCHAD Isolated LCHADD HADHB 600890 
LCKAT Isolated LCKAT 
deficiency 
HADHB 143450 
MCAD MCADD ACADM 201450 
MCKAT MCKAT deficiency Unknown 602199 










ETF β-subunit EFTB 
*formerly known as SCHAD 
 
 
2.2.3. The biochemical diagnosis of FAOD  
Initial laboratory studies usually include serum glucose, electrolytes, lactate, 
ammonia, transaminases, creatine kinase and urine analysis. Hypoglycaemia is 
usually present, but normal to borderline levels may be observed. Serum lactate 
may be moderately increased, and mild elevations of plasma ammonia levels 
(up to 100 μmol/l; reference range (ref. <50 μmol/l)) may be observed. Liver 
dysfunction and elevated creatine kinase activity is more prominent in 
LCHADD patients, being present in 89% and 67% of patients respectively (den 
Boer et al., 2002). 
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 Biochemical diagnosis of FAOD commonly begins with a search for 
diagnostic metabolites in physiological fluids. This is followed by in vitro 
functional studies if the initial findings are inconclusive, and is confirmed by 
enzymology and molecular analyses (den Boer et al., 2002). 
 
2.2.3.1. Organic acid analysis 
Methods to identify abnormal metabolites of FAs using gas chromatography 
coupled to mass spectrometry (GC/MS) have been available since the mid-
1970s (Roe 1995). Changes in urinary organic acid analysis are detectable in β-
oxidation defects, where the accumulation of chain-specific metabolites can be 
detected. In the case of carnitine cycle defects, no abnormalities are detected in 
the GC/MS analysis of urinary organic acids (Roe 1995). 
 The general changes characteristic of most FAO defects are the absence or 
low excretion of ketones. Key metabolites detected in the urinary organic acid 
analysis suggestive of FAO defect are dicarboxylic acids arising from micro-
somal ω-oxidation, and acylglycines (Roe 1995). The changes suggestive of 
specific blockage in β-oxidation are given in table 4. 
 
 
Table 4. The changes characteristic of FAO defects observed in GC/MS analysis of 
organic acids.  
 
Defect Dicarboxylic acids Acylglycines 
VLCADD  C12-C14  dicarboxylic acids Not present 
LCHADD  3-OH dicarbocylic acids (C6-C14)  
C6-C10 dicarboxylic acids  
Not present 
MCADD  C6-C10 dicarboxylic acids  Hexanoylglycine 
Suberylglycine 
SCADD  Ethylmalonate 
Methylsuccinate 
Butyrylglycine 
MADD  Isovaleric acid 
Isobutyric acid 
2-methylbutyric acid 












It must be emphasised that dicarboxylic acid excretion is not pathognomic to 
FAOD, as they can also be observed in diabetic ketoacidosis and after the 
dietary administration of medium chain triglycerides (MCT). The concentra-
tions of abnormal urinary metabolites vary greatly: they may be below detection 
level if the patient is well. Therefore samples obtained during an acute episode 
are most informative (Roe and Coates 1995). 
 
2.2.3.2. Tandem mass-spectrometry  
MS/MS can be applied in different fields of biochemical genetics. The techni-
que is most commonly performed using a triple quadrupole mass spectrometer, 
which consists of an ionisation source, three mass filters connected in tandem 
and a detector. Ions produced in the source are selected by the first quadrupole 
(Q1) for transmission to the second quadrupole, which is designated as the 
collision cell. In this region, the ions are accelerated and collide with molecules 
of an inert collision gas and undergo collision-induced dissociation. The frag-
ments produced are transmitted to the final quadrupole (Q3), where they are 
again selected for transmission to the detector. The MS/MS can be operated to 
scan for all fragments produced from a single precursor (product ion scan), all 
precursors producing a single product (precursor ion scan), or to scan both 
filters of a fixed mass separately to select all precursors undergoing a loss of 
common noncharged moiety (neutral loss scan). Multiple reaction monitoring 
(MRM), also referred to as selective reaction monitoring (SRM), is used. In this 
mode Q1 is fixed to the precursor ion and Q3 to a characteristic fragment 
(Carpenter and Wiley 2002).  
 The biochemical diagnosis of FAOD relies on acylcarnitine profiling (ACP) 
using MS/MS. The defect in β-oxidation will lead to an increased accumulation 
of fatty acyl-CoA molecules of chain-specific length that cannot be further 
metabolised. These metabolites are not able to exit mitochondria, but esterifying 
to carnitine and formation of acylcarnitines allows transportation across 
compartments, making measurement possible.  
 All disorders of the carnitine cycle and β-oxidation can be detected on ACP 
(table 5). This analysis is also informative in some disorders of organic acid 
metabolism, which cause accumulation of acyl-CoAs (not given). 
Carnitine and its esters are found in virtually all biological fluids. The 
preferred sample type for the testing of symptomatic patients and asymptomatic 
at risk individuals is plasma or serum (Rinaldo et al., 2008). Testing from dried 
blood spots is used in NBS. ACP from urine can be used when there is a 
suspicion of organic aciduria. Post-mortem screening can be performed on 
dried-blood spots or bile (Chace et al., 2001), and amniotic fluid can 




Table 5. The key metabolites detected during ACP by MS/MS. * Mass to charge ratio 
[M+H]+ is given for molecules where the carnitine carboxyl group has been derivatised 
into butyl esters. 
 




Free carnitine ↑ C0 218 C16, C18↓ 
SCADD  Butyrylcarnitine↑ C4 288 – 




C4-OH 304  
MCADD  Octanoylcarnitine↑ C8 344 C6, C10, C10:1 
VLCADD  Tetradecenoylcarnitine↑ C14:1 426 C14, C14:2 
CPT2 
deficiency 
Palmitoylcarnitine↑ C16 456 C18:2, C18:1, C18 
CACT 
deficiency 
Palmitoylcarnitine↑ C16 456 C18:2, C18:1, C18 
LCHADD  3-hydroxypalmitoyl-
carnitine↑ 











2.2.4. Confirmation of the diagnosis of FAOD  
The diagnosis of FAOD relies largely on the above-mentioned biochemical 
investigations, which are informative for all disorders of the carnitine cycle and 
β-oxidation. If the biochemical changes are suggestive of the specific disorder, 
confirmation of the diagnosis at the enzymatic or molecular level is necessary 
(Derks et al., 2008; Tyni and Pihko 1999). 
 
2.2.4.1. Molecular analysis 
Molecular studies in FAOD are performed using genomic DNA extracted from 
peripheral blood lymphocytes. In addition to the molecular confirmation of 
FAOD, genetic analysis makes it possible to establish genotype-phenotype 
relationships, which has implications for the prognosis and treatment options in 
some disorders (Sim et al., 2002). 
 As all inherited FAOD are caused by mutations in different genes (table 3), 
the genetics of MCADD and LCHADD are discussed below, as these disorders 







LCHAD is one of the three enzymes of the MTP enzyme complex. The other 
enzymes of the same complex are long-chain 2,3-enoyl-CoA hydratase (LCEH) 
and long-chain 3-ketoacyl-CoA thiolase (LCKAT). MTP is a heterocomplex 
composed of four α-subunits that contain LCEH and LCHAD and four β-
subunits that harbour LCKAT activity (Choi et al., 2007; Tyni and Pihko 1999). 
LCEH activity resides in the N-terminal and LCHAD activity in the C-terminal 
part of the α-subunit. Therefore MTP deficiency is classified into two cate-
gories: the more common isolated LCHADD with the defects of α-subunits 
encoded by the HADHA gene and the less common pattern of complete MTP 
deficiency involving deficiencies of all three enzymes with defects of the α- and 
β-subunits encoded by the HADHB gene (table 3). Like all disorders affecting 
β-oxidation, MTP deficiency and LCHADD are inherited autosomal reces-
sively. 
 The HADHA gene responsible for isolated LCHADD is located in the short 
arm of chromosome 2 (2p23.3). It contains 20 exons spanning over 52 kb (Sims 
et al., 1995). Over 30 gene variations in the HADHA gene have been described 
so far (Gregersen and Olsen 2010), among them c.1528G>C (p.E510Q; 
NM_000182.4),  which is by far the most common mutation, accounting for 
87% all LCHAD alleles (Jlst et al., 1994). This missense mutation results in the 
substitution of glutamate to glutamine at amino acid position 510. The base 
substitution creates a PstI restriction site (Jlst et al., 1994). As this change is 
located in a catalytically active region, it deteriorates the dehydrogenase activity 
of -subunit protein (Ijlst et al., 1996; Sims et al., 1995).  
 The carrier frequencies of this common mutation have been evaluated in a 
few populations, including some neighbours of Estonia (den Boer et al., 2000; 
Ibdah et al., 1999; Piekutowska-Abramczuk et al., 2010; Zhu et al., 2005; Tyni 
and Pihko 1999) (table 6). 
 
 
Table 6. The carrier frequencies of mutation c.1528G>C in HADHA gene in different 
populations. 
 






Finland 1200/5 1:240 Tyni and Pihko 1999 
The Netherlands 2047/3 1:680  den Boer et al., 2000 
Poland 2161/10 1:216 Piekutowska-
Abramczuk et al., 2010 
China (Han) 1200/0 ND Zhu et al., 2005 
USA 351/2 1:175 Ibdah et al., 1999 






The human ACADM gene encoding MCAD is located on chromosome 1p31 
(Matsubara et al., 1986) and spans 44 kb. It contains 12 exons encoding a 
mature protein of 396 amino acids (Zhang et al., 1992). More than 30 mutations 
of the ACADM gene have been identified; most of these are missense mutations 
(Kennedy et al., 2010). 
 The most prevalent mutation, c.985A>C (p.K304E), has been detected in 
91% of mutant alleles in Japanese MCAD patients (Matsubara et al., 1990). 
Andresen et al evaluated the genetics of MCADD in patients diagnosed pro-
spectively by MS/MS based screening from a cohort of >900,000 newborns. In 
this cohort 80% of MCADD patients were homozygous for the common 
mutation, whereas a further 18% have this mutation in only one disease allele 
(Andresen et al., 2001).  
 It has previously been shown that the carrier frequency for the common 
mutation in the ACADM gene in the Estonian population is 1:220 in a series of 
1,098 newborns born during one month in Estonia (Lilleväli et al., 2000). 
 
2.2.4.2. Enzyme analysis 
Assays of the enzyme activities of the FAO pathway may be performed in 
cultured skin fibroblasts, tissue biopsies or lymphocytes (Roe 1995; Wanders 
and Ijlst 1992). The determination of FAO enzyme activities usually involves 
measurement of enzyme activity with substrates of different chain lengths and 
activity ratio studies (Sim et al., 2002). The specific measurement of acyl-CoA 
dehydrogenases (ACAD) requires: (a) a specific substrate, preferably reactive 
with only one particular ACAD (b) a specific detection system allowing the 
activity of each ACAD to be measured. The specific substrates used in β-
oxidation defects are butyryl-CoA, 3-phenylproprionyl-CoA and palmitoyl-CoA 
in SCAD, MCAD and VLCAD respectively. The ACAD activities are usually 
measured spectrometrically – HPLC coupled to ultraviolet-defection or ultra-
performance liquid chromatography coupled to MS/MS detection (Wanders et 
al., 2010). 
 
2.2.5. The clinical picture of FAOD  
In general, FAOD have three different clinical presentations. The first is 
Reye-like syndrome associated with hypoketotic hypoglycaemia, which is 
triggered by a catabolic state and often manifests in association with 
intercurrent disease. This is the most severe clinical manifestation, lethal in a 
significant proportion of patients and presenting often in the neonatal period 
or in infancy. Patients may also present with cardiac symptoms such as 
dilatated or hypertrophic cardiomyopathy and cardiac arrhythmias. The milder 
form of the disease manifests in later life and is characterised by exercise-
induced myopathy and rhabdomyolysis. This group of IEMs has also been 
associated with SIDS due to hypoglycaemia or cardiac disease (Roe 1995; 
Yamamoto et al 2010; Pryce et al 2011). 
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2.2.5.1. The clinical picture of LCHADD 
In a series of 50 LCHADD patients, Den Boer et al (2002) observed that the 
majority (78%) of patients present in infancy with an acute metabolic derange-
ment manifesting with hepatic dysfunction, coma and seizures or cardiac 
symptoms. Primary manifestation with SIDS was observed in 9% of patients. 
Twenty-two percent of patients presented with a more chronic disorder, 
consisting of liver disease, failure to thrive, feeding difficulties and hypotonia. 
The mortality in this series was high (38%). 
 Mental development in LCHADD patients is usually normal despite delayed 
motor development in infancy. Psychomotor retardation and epilepsy have only 
occasionally been found (Tyni and Pihko 1999).   
 All symptoms are reversible with sufficient energy supply. Disease-specific 
symptoms occur in some long-chain FAODs. Only in disorders of the TFP 
complex, including LCHADD, do progressive and irreversible neuropathy and 
retinopathy develop despite current treatment measures (Spiekerkoetter 2010a). 
 Peripheral neuropathy is an important clinical symptom of LCHADD and 
MTP deficiency and distinguishes these disorders from other FAOD (Tyni and 
Pihko 1999). Peripheral neuropathy has been described in 10% of LCHADD 
patients (den Boer et al., 2002).  
 Ophthalmological findings are frequent features of LCHADD found in 63% 
of patients (Tyni et al., 1998) and may be apparent from the age of 4 months. In 
the preliminary stages of eye disease, pale fundus is observed, which progresses 
to the retinal pigmentary chorioretinopathy. The changes in eye fundi have been 
associated with the accumulation of 3-hydroxylated compounds (Roomets et al., 
2008). In addition to above-mentioned symptoms affecting the peripheral ner-
vous system and eyes, complications of pregnancy such as hemolysis, elevated 
liver enzymes, low platelets (HELLP) syndrome, acute fatty liver of pregnancy 
(AFLP) have been described in relationship to LCHADD in the fetus (den Boer 
et al., 2000; Tyni and Pihko 1999). 
 In general, LCHADD and TFP deficiency could not be clinically distin-
guished in their acute clinical presentations and long-term complications. 
However, significantly lower survival has been observed in patients with TFP 
deficiency (Primassin et al., 2010; Spiekerkoetter 2010b). 
 
2.2.5.2. The clinical picture of MCADD 
The clinical picture of MCADD is not complex compared to LCHADD. 
MCADD usually presents in childhood with an episode of vomiting and 
lethargy following a period of fasting. Often this episode is preceded by viral 
infection associated with decreased oral intake. Some patients have a history of 
previous similar episodes. On presentation to the hospital, a child may be coma-
tose with hypoglycaemia and often there are low to moderate levels of ketones 
in urine. Intravenous infusion with 10% glucose yields a rapid improvement. 
The patients are usually asymptomatic between episodes (Roe 1995).  
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 Adult presentations (age 16–45 years) with sudden clinical deterioration 
precipitated by fasting or alcohol consumption have been described (Lang 
2009). MCADD deficiency in mother in relationship with AFLP have been 
described in one woman (Santos et al., 2007). 
 Although episodes resolve rapidly with adequate treatment, the mortality of 
infantile patients is approximately 25%  and is even higher in acutely presenting 
adult patients (50%) (Lang 2009).  
 
2.2.6. The epidemiology of FAOD  
The era of expanded NBS has significantly changed the understanding of the 
prevalence of FAO defects. According to the preliminary data from NBS from 
Australia, Germany and USA, the combined incidence of FAO defects is 1:9300 
(Lindner et al., 2010). NBS have demonstrated that disorders such as MCADD 
and VLCADD are more prevalent than previously suspected. Carnitine cycle 
defects are still extremely rare disorders, with CPT1 deficiency less than 50 
known cases worldwide. The prevalence of CPT2 deficiency is slightly higher, 
with less than 400 published cases. 
 
2.2.6.1. The epidemiology of LCHADD 
Before expanded NBS, the estimated incidence of LCHADD was >1:250,000 
(Chace et al., 2003). The NBS screening data from Australia, Germany and 
USA indicate that in those countries LCHADD incidence remains low, but data 
from selective screening from Poland, where LCHADD prevalence is 118,336 
(Piekutowska-Abramczuk et al., 2010), make it possible to estimate higher 
incidence, at least in some populations. This observation is supported by the 
relatively high carrier frequencies observed in some populations (table 6). 
 
2.2.6.2. The epidemiology of MCADD 
The incidence of MCADD in the “pre-screening era” was estimated at about 1: 
25,000 (Chace et al., 2003). Expanded NBS has revealed that the overall 
frequency of this disorder generally ranges from 1:4900 to 1:17,000 and 
demonstrates significant variations among different populations. The incidence 
of MCADD based on available data from expanded NBS is given in table 7. 
 
 
Table 7. The incidence of MCADD in different countries. 
 
Population  Incidence/newborns Reference 
Northern Germany 1:4900 Sander et al., 2001 
Southern Germany 1:8500 Maier et al., 2005 
England 1:10,000 Oerton et al., 2011 
The Netherlands 1:6,600 Derks et al., 2008 
Ontario (USA) 1:14,000 Kennedy et al.,2010  
Taiwan 1:700,000 live births Niu et al., 2010 
Japan 1:51,000 Shigematsu et al., 2002 
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2.2.7. The treatment of FAOD  
The clinical symptoms of FAOD arise due to inadequacy of energy and the 
accumulation of metabolites secondary to enzymatic block. Therefore thera-
peutic approaches have two goals: to prevent the accumulation of potentially 
toxic metabolites such as acyl-CoA esters and to circumvent the metabolic 
block providing alternative energetic substrates.  
 In order to counteract the accumulation of toxic metabolites, dietary 
reduction of those metabolites (particularly long-chain fatty acids (LC-FA)) and 
the promotion of detoxification through carnitine supplementation are applied.  
Adequate energy consumption is ensured with high amounts of carbohydrates 
and by substituting LC-FA with medium-chain fatty acids (MC-FA). Although 
the restriction of dietary fat is no longer a mainstay in VLCADD, MCT seems 
to prevent episodic myopathic symptoms triggered by exercise. In LCHADD, 
however, the strict restriction of LC-FA is necessary to avoid the accumulation 
of toxic long-chain 3-hydroxyacylcarnitines and CoA esters (Spiekerkoetter et 
al., 2009a; Spiekerkoetter et al., 2009b). 
 Of course MC-FAs are not used in the treatment of MCADD – avoidance of 
fasting is the principal treatment measure for this defect. Carnitine supple-
mentation is applied if free carnitine is low (Zschocke and Hoffmann 2011). 
 The avoidance of fasting in all FAOD is undoubtedly beneficial in terms of 
disease outcome, can be life-saving in many cases and is the main reason why 
early diagnosis of FAOD is vital. The preliminary data from expanded NBS, 
which includes FAOD, permit one to conclude that the outcome of FAOD and 
other metabolic diseases included in the screening panel in presymptomatic 
diagnosis is as good as in PKU (Lindner et al., 2011). 
 
2.3. Mitochondrial disorders 
2.3.1. An introduction to MD 
MDs are disorders of the enzymes or enzyme complexes directly involved in the 
generation of chemical energy through the oxidative phosphorylation system 
(OXPHOS). Mitochondriopathies arise due to mutations in genes of mito-
chondrial DNA (mtDNA) or nuclear DNA (nDNA) encoding for mitochondrial 
proteins with enzymatic, structural, signalling, channelling, transport, receptor 
or assembling functions (Finsterer 2004). A defect in OXPHOS can be 
clinically suspected in every patient with an unexplained combination of neuro-
muscular and/or non-neuromuscular symptoms with progressive disease course 
(Munnich and Rustin 2001). The clinical spectrum is extremely wide and has 
overlapping features. The single mutation in mtDNA or mutations in the same 
gene may present with different clinical manifestations, or the same phenotype 
may be caused by different mutations (Finsterer 2004). Mitochondrial 
dysfunction contributes to pathophysiological mechanisms underlying common 
diseases such as neurodegenerative diseases (Alzheimer’s disease, amyotrophic 
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lateral sclerosis, Huntington’s disease), cardiovascular disease, diabetes and 
cancer (DiMauro and Schon 2003; Koene 2011). 
 Mitochondrial pathology was first described in 1962 by Luft el al in a 
hypermetabolic patient (Luft et al., 1962). The first patient was a 35-year-old 
woman who presented with profuse perspiration, polydipsia without polyuria 
and progressive asthenia despite polyphagia since the age of 7. Biochemical 
studies revealed loosely coupled state of the oxidative phosphorylation in the 
patient’s mitochondria and electron microscopic study showed an increased 
amount of mitochondria with aberrant structure. An increased amount of total 
mitochondrial protein was also observed with increased cytochrome oxidase 
(COX) activity (Luft et al., 1962).  
 In 1963 W. King Engel introduced a simple histochemical assay – a modi-
fication of a Gomori trichrome stain that allowed the detection of abnormal 
mitochondrial proliferation in muscle – ragged red fibres (RRF) (Dimauro 
2011).  
 Although mtDNA has been known since 1963 (Nass and Nass 1963a; Nass 
and Nass 1963b), the sequence and organisation was described in 1981 by 
Anderson et al (1981). The first mtDNA mutations were described in patients 
with mitochondrial myopathy (Holt et al., 1988) and Leber hereditary optic 
neuropathy (LHON) (Wallace et al., 1988). In 1989 Zeviani described multiple 
mtDNA deletions in the muscular tissue of patients with progressive external 
ophthalmoplegia (PEO) and related these to faulty communication between 
nuclear and mitochondrial genomes (Zeviani et al., 1989). Subsequently, in 
1991 the quantitative defect of mtDNA, mtDNA depletion was described in 
patients with autosomal recessive diseases affecting the muscles or liver  (Mo-
raes et al., 1991).  
 In 1992 the first nuclear mutation was described in two sisters with Leigh 
syndrome (Burgeois et al., 1992). The first molecular causes for mtDNA 
depletion were identified in 2001. Saada et al identified mutations in the 
tymidine kinase-2 (TK2) gene in patients with mitochondrial depletion myo-
pathy (Saada et al., 2001) and the mutations in the deguanosine kinase 
(DGUOK) gene in depleted hepatocerebral mtDNA were first described by 
Mandel et al (Mandel et al., 2001). To date > 100 point mutations in mtDNA 
are known (Finsterer 2004), and > 100 genes in nuclear DNA are known to 
affect energy production by OXPHOS. 
 
 
2.3.2. The metabolism of MD 
Mitochondria are the double-membrane organelles that are present in the 
cytosol of virtually all eukaryotic cells and play a crucial role in energy 
production. The mitochondrial inner membrane surrounds the mitochondrial 
matrix and is not smooth, but displays many protrusions. This serves to enhance 
the mitochondrial surface area, which is beneficial for the metabolic reactions 
occurring in the inner membrane and in the mitochondrial matrix (e.g. FAO, 
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pyruvate oxidation, tricarboxylic acid (TCA) cycle, UC, and heme biosynthesis) 
(Valsecchi et al., 2010). 
 MD affects enzymes or enzyme complexes directly involved in the 
generation of chemical energy via oxidative phosphorylation. These include 
disorders of pyruvate metabolism, the TCA cycle, the mitochondrial respiratory 
chain (RC) and ATP synthase (Zschocke and Hoffmann 2011). A schematic 
overview of those pathways is offered in figure 2. 
 The central substrate for energy production is acetyl-CoA, which is produced 
by β-oxidation (figure 1) and pyruvate metabolism. Pyruvate is mostly formed 
via glycolysis in the cytosol and can be reversibly converted to lactate by lactate 
dehydrogenase (LDH) and to alanine by alanine aminotransferase (ALT). 
Pyruvate enters the mitochondrion and is subsequently decarboxylated into 
acetyl-CoA by the PDH complex. The PDH complex consists of 96 subunits 
organised into three functional proteins: pyruvate decarboxylase (E1), dihydro-
lipoyl transacetylase (E2) and dihydrolipoyl dehydrogenase (E3) (Robinson 
1995). 
 The resulting acetyl-CoA enters the TCA cycle and is bound to oxaloacetate 
to form citrate. The cycle consists of nine enzymatic conversions (figure 2) and 
produces NADH and succinate for OXPHOS complexes I and II respectively. 
For each acetyl group entering the TCA cycle, three molecules of NADH are 
produced. At the end of each cycle, the four-carbon oxaloacetate has been 
regenerated and the cycle continues (Wallace et al., 2010). 
 
 




The RC is composed of five enzyme complexes that contain flavins (FMN, 
FAD), quinoid complexes (CoQ10) and transition metal compounds (iron-sulfur 
clusters, hemes and protein-bound copper). These complexes are located in the 
mitochondrial inner membrane and are designated as complex I 
(NADH:ubiquinone oxidoreductase), complex II (succinate:ubiquinone oxidore-
ductase), complex III (ubiquinol:ferrocytochtome c oxidoreductase), complex 
IV (cytochrome c oxidase) and complex V (ATP synthase).  
Complex I is the largest complex of the electron transport chain and has a 
major function in oxidative phosphorylation, as its main task is the electron 
transfer from NADH to ubiquinone, a lipid-soluble carrier of the inner 
mitochondrial membrane. The energy that originates from this process is used 
to move protons across the inner membrane, creating an inside negative memb-
rane potential (Distelmaier et al., 2009). Complex II catalyses the oxidation of 
succinate to fumarate, coupled to the reduction of ubiquinone (CoQ) to 
ubiquinol. The electrons extracted from fumarate are transferred to FADH, 
which passes them to the three Fe-S clusters and cytochrome b to CoQ. 
Complex II has no proton pumping activity (Koene 2011). 
 Complex III passes electrons from CoQ to cytochrome c and pumps protons 
across the mitochondrial inner membrane (Koene 2011). Complex IV is the 
final protein complex in the electron transport chain and donates electrons to 
oxygen, leading to the formation of water (Koene 2011). Finally, complex V, 
which is the final enzyme of the OXPHOS pathway, uses the energy stored in a 
proton gradient across the inner mitochondrial membrane to phosphorylate ADP 
to ATP (Jonckheere et al., 2011). 
 In this sense, mitochondria are the key players in cell energy, redox balance 
and survival, but mitochondria are also crucial for apoptosis induction and Ca2+ 
homeostasis  (Valsecchi et al., 2010).  
   
 
2.3.3. The genetics of MD 
2.3.3.1. Mitochondrial DNA 
MtDNA (figure 3) is a 16.6 kb circular double-stranded molecule, which 
consists of two strands differentiated by their nucleotide content. The guanine-
rich strand is referred to as the heavy strand, and it encodes 28 genes. The 
cytosine-rich strand is referred to as the light strand, and it encodes 9 genes 
(Finsterer 2004). The genes encoded by mtDNA include: 2 mitochondrial 
ribosomal RNAs (rRNA) and 22 transfer RNAs (tRNA), 7 subunits of complex 
I, 1 cytochrome b (complex III) and 1 cytochrome c oxidase (complex IV) and 2 




Figure 3. The structure of the mitochondrial genome. Adapted from MITOMAP 
(http://www.mitomap.org/MITOMAP/MitomapFigures). The location of genes re-
sponsible for OXPHOS function and more frequent mutations is shown. The D-loop 
region controls the initiation of the replication of mtDNA. 
 
 
MtDNA is different from nDNA in many senses: it has no introns and 93% of it 
is responsible for coding; its structure is circular and it is not interwoven with 
histones. MtDNA has a mutation rate 10–20 times higher than nDNA and no 
effective repair system (Finsterer 2004).  
 Each cell contains thousands of mtDNA molecules and in general 
pathogenic mutations are not present in all of them. The situation in which both 
normal (wild-type) and mutant mtDNA is present in the cell and/or tissue is 
known as heteroplasmy.  This phenomenon is known to exist at the organelle 
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level as well: a single mitochondrion can harbour both normal and mutant 
mtDNAs. Individuals with all identical mtDNAs are homoplasmic (DiMauro 
and Schon 2003).  
 The clinical symptoms of MD due to mtDNA mutations are dependent on 
the ratio between mutant and wild-type DNA – the threshold effect. The 
threshold for disease is lower in tissues that are highly dependent on oxidative 
metabolism, such as the brain, heart, skeletal muscle, retina, renal tubules, and 
endocrine glands (DiMauro and Schon 2003). 
 Generally all mitochondria and mtDNA are inherited from the mother, and 
therefore MD follow maternal inheritance. Since mitochondria from sperma-
tozoid are labelled for destruction by ubiquination after fertilisation, mtDNA 
mutations from the mother are transmitted to all offspring (Koene 2011). 
Paternal inheritance of mitochondrial haplotype has been reported only once, in 
a family where the index patient had a deleterious mitochondrial mutation 
causing myopathy (Schwartz and Vissing 2002). 
 The clinical outcome of mitochondrial disease due to mtDNA mutation is 
mitotic segregation. This is the random redistribution of cell organelles during 
the cell division that can change the proportion of mutant mtDNA received by 
daughter cells (Figure 4). Age- and tissue-related variabilities arise from this 




Figure 4. Mitotic segregation: the variable distribution of wild-type and mutated 
mtDNA (from Zeviani and Antozzi 1997). 
 
 
2.3.3.2. Nuclear DNA 
Nuclear-encoded factors are related to mitochondrial biogenesis, complex 
assembly, mtDNA replication, transcription and mitochondrial protein bio-
synthesis. It is estimated that about 1500 mitochondrial proteins are influenced 
by nuclear genes (Wong 2010). An overview of nuclear genes targeted to 
mitochondria is given in table 8.  
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Table 8. An overview of nuclear genes targeted to mitochondria, adapted from Wong 














Apoptosis 50 Metabolism 350 Proteases 25 Immune 2 
Chaperone 20 Dynamics 10 Nucleases 5 Protein 
import 
30 
Cytochromes 15 Replication 10 RNA mod 5 ROS** 15 




DNA repair 12 Regulation 5 MRP* 91 Other 175 
Fe-S cluster 3 Porins 4 tRNA 
synthase 









10   
 
 
Nuclear genes associated with the development of MD are responsible for a) 
mtDNA maintenance; b) the encoding of OXPHOS complex subunits and the 
proteins involved in their assembly; c) biosynthesis of CoQ. 
 The defects in genes involved in mtDNA synthesis and mitochondrial 
dynamics lead to a reduction in cellular mtDNA content. To date 12 genes 
related to DNA repair are known (table 8), and majority of them (table 9) have 
been found to result in DNA depletion with tissue-specific involvement (Wong 
2010). Although TK2 and DGUOK were the first genes to be related to mtDNA 
depletion (Dimauro 2011), the mutations in the POLG1 gene are the most 
common nuclear gene defects causing MD, including diseases arising from 
DNA depletion. POLG1 encodes the catalytic subunit of the polymerase 
gamma, which is the only mtDNA polymerase and one of the three essential 
factors required for mtDNA replication (Suomalainen and Isohanni 2010).  
 There are over 100 nuclear genes coding for proteins involved in OXPHOS 
complex subunits and their assembly (table 8). Molecular defects of OXPHOS 
subunit genes or genes essential for complex assembly may be associated with 
isolated complex deficiency depending on the defective gene (Wong 2010). The 
most common of these disorders are defects in complex IV (cytochrome c 
oxidase) assembly factors caused by mutations in 8 genes (table 9). Complex I, 
the largest RC complex, is regulated by a number of genes (table 9). Mutations 
in these genes generally have a dramatic effect on neurodevelopment and over-
all patient survival (Distelmaier et al., 2009). The BCS gene, located at 2q33, is 
the leading cause of isolated complex III deficiency (Wong 2010).  Finally, 
complex V deficiency is often related to mutations in TMEM70 (Jonckheere et 
al., 2011).  
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 Nuclear genes also affect the CoQ pathway, which is essential for RC 
function. Genes involved in CoQ biosynthesis (PDSS1, PDSS2, COQ2, CABC1, 
COQ9) cause primary CoQ deficiency, leading to deficiency of complexes I, 
II+III (Zschocke and Hoffmann 2011), clinically manifesting as mitochondrial 
encephalomyopathy (Wong 2010). 
 Additionally, there are genes that have an indirect influence on mitochondrial 
function. These are the genes involved in mitochondrial protein importation, such 
as TIMM8A encoding for the deafness-dystonia protein, a component of the 
mitochondrial-protein-import machinery in the intermembrane space. Mutations 
in TIMM8A are responsible for the deafness-dystonia syndrome (Mohr-
Tranebjaerg syndrome), an X-linked recessive disorder characterised by progres-
sive neurosensory deafness, dystonia, cortical blindness and psychiatric symp-
toms (DiMauro and Schon 2003). In addition, genes influencing fusion and 
fission dynamics, such as OPA1 (located 3q29), which encodes mitochondrial 
dynamin-related guanosine triphosphatase, belong to this group. Mutations in this 
gene cause autosomal dominant optic atrophy, which causes blindness in young 
adults (DiMauro and Schon 2003). The indirect involvement of mitochondria has 
been related to many “common” conditions as normal aging, late-onset neuro-
degenerative diseases and cancer (DiMauro and Schon 2003). 
 The majority of nuclear-encoded MD are inherited autosomal recessively 




Table 9. The classification of nuclear genes causing MD according to the function and 
mode of inheritance. 
 




mtDNA maintenance POLG, DGUOK, MPV17, TK2, 





































BCS1, HCCS, TTC19   
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SURF1, COX10, COX15, SCO1, 
















TSFM, TUFM, DARS2, RARS2, 
SARS2, YARS2, TRMU, 
C12ORF65, MTPAP, SPG7, 
AFG3L2 
  
CoQ biosynthesis COQ2, PDSS1, PDSS2, 
ADCK3, COQ9 
  
















   
2.3.4. The clinical picture of MD 
Genetic disorders of the mitochondrial RC are a clinically heterogeneous group 
of disorders affecting the body’s energy production. They may present at any 
age and affect any organ (Munnich and Rustin 2001). As cells with high-energy 
requirements such as neurons, skeletal and cardiac muscle are particularly 
vulnerable to limited ATP supply, encephalopathy and myopathy are often 
prominent features in the various mitochondrial phenotypes.  
 Mitochondrial energy production functions early in embryo-fetal develop-
ment (Illsinger and Das 2010). Antenatal manifestations of RC disorders have 
been described infrequently, and they are probably related to the time course 
and tissue specificity of the underlying gene. The relationship of TMEM70 
mutations causing oligohydramnion in the third trimester of pregnancy was 
recently described (Spiegel et al., 2010). Patients with PDH deficiency may 
present antenatally with brain anomalies including agenesis of the corpus 
callosum, cystic lesions of the brain and microcephaly (Illsinger and Das 2010).  
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 OXPHOS disorders may manifest in neonates with a combination of 
nonspecific symptoms such as prematurity and intrauterine growth retardation 
(IUGR) with early postnatal decompensation, poor feeding, or vomiting and 
persisting lactic acidosis. Distinct clinical forms may also be observed: neonatal 
encephalopathy with seizures, intestinal dysmotility, liver disease and cardio-
myopathy (Illsinger and Das 2010).  
 In the series of 129 patients with neonatal onset of MD Honzik et al (2010), 
muscular hypotonia was the most frequent clinical manifestation, presenting in 90% 
of patients. Thirty percent of patients needed ventilatory support due to muscular 
hypotonia. The other clinical presentations of MD in neonatal age were 
cardiomyopathy, seizures and LS, occurring in 40%, 16% and 15% of patients 
respectively. The neonatal origin of MD was associated with TMEM70 mutations in 
22 out of 129 patients. The other genes associated with the neonatal origin of the 
disease were: PDHA1, SCO2, DLD, SCO1, POLG, TAZ, NDUFS4, ATP5E and 
SUCLG1. Mutations in mtDNA were detected in 14 patients (Honzik et al., 2012). 
 The most common childhood-onset mitochondrial disease is LS (Kisler et 
al., 2010). LS or subacute necrotising encephalopathy is characterised by 
psychomotor retardation usually occurring between 3–12 months of age. Addi-
tional neurological, endocrine, renal or cardiac abnormalities may be present. 
LS has a specific finding on brain magnetic resonance imaging (MRI), which 
reveals symmetric hyperintensities on T2-weighted images in the basal ganglia, 
brainstem, thalamus, diencephalon and cerebellum (figure 9). LS is a progres-
sive disease and has a poor prognosis (Koene 2011).  
 Myopathy is the most prominent symptom of MD in all ages. Patients may 
have normal or slightly elevated serum creatine kinase activity, and the results 
of electromyography are usually normal. Therefore it is reasonable to suspect a 
MD in patients with significant muscular hypotonia accompanied by normal 
electromyography and creatine kinase (Koenig 2008).  
 Seizures are a frequent symptom in MD. They may occur as a presenting 
symptom or may be part of a multisystem disease. The explosive onset of focal 
epilepsy, epilepsia partialis continua or status epilepticus, should arouse suspi-
cion of Alpers syndrome, but otherwise mitochondrial epilepsies are genetically 
heterogeneous. The more common genetic causes for seizures associated with 
mitochondrial dysfunction are mtDNA and POLG mutations (Rahman 2012). 
Patients with MD are particularly sensitive to valproate-induced liver failure, 
and therefore MD should be considered in any child presenting with valproate-
induced liver dysfunction (Koenig 2008). 
 Growth failure is present in about 20% of mitochondrial patients, and neuro-
sensory hearing loss, progressive external ophtalmoplegia, axonal neuropathy, 
diabetes mellitus, and renal tubular acidosis are also important symptoms of RC 
dysfunction (Koenig 2008).  
 In some cases MD presents as clinical syndromes with the involvement of 
different organ systems. Syndromic presentation is more characteristic of 
mtDNA mutations, but sometimes points to certain nuclear genes. An overview 
of mitochondrial syndromes is offered in table 10. 
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Table 10. An overview of the mitochondrial clinical syndromes * DIDMOAD- diabetes 
insipidus, diabetes mellitus, optic atrophy and deafness. 
 
Syndrome Clinical feature Age of onset Genetic defect 
LHON Leber hereditary optic neuro-
pathy, subacute painless visual 
loss 
12–30 years m.11778G>A (MT-ND4) 
m.3460G>A (MT-ND1) 
m.14484T>C (MT-ND6) 
NARP Neuropathy, ataxia, retinitis 
pigmentosa 
5–30 years m.8993T>G/C (MT-ATP6) 
MELAS Mitochondial encephalo-
myopathy, lactic acidosis, 
stroke-like episodes 
5–15 years m.3243A>G (MT-TL1) 
KSS Kearns-Sayre syndrome: PEO, 
pigmentary retinopathy, 
cardiac conduction block, 
cerebellar ataxia, CSF protein 
>0,1 g/l 
<20 years mtDNA deletions  
duplications 
PEO Bilateral ptosis, limited eye 
movement 
20–30 years Single mtDNA deletion; 
POLG, POLG2, RRM2B,  
C10ORF2, SLC25A2  
MERFF Myoclonic epilepsy with 
ragged red fibres 
5–15 years m.8344G>A (MT-TK) 
MIDD Maternally inherited diabetes 
and deafness 
20–30 years m.3243A>G (MT-TL1) 
Alpers Progressive neuronal degene-
ration of childhood (seizures+ 
liver involvement) 
Early childhood POLG, rarely C10ORF2 
Barth Cardiomyopathy, cyclical 
neutropenia, myopathy, short 
stature 
Neonate/infancy TAZ 
DCMA Dilatated cardiomyopathy with 
ataxia, neutropenia, myopathy 
Neonate/infancy DNAJC19 
GRACILE Growth retardation, aminoaci-
duria, cholestasis, iron 
overload, lactic acidosis, early 
death 
Neonate/infancy BCS1L 
Wolfram  DIDMOAD*, bladder instabi-
lity, ataxia, peripheral neuro-
pathy, dementia, psychiatric 
disorders, seizures 
3–40 years WFS1, WFS2 
MLASA Myopathy, lactic acidosis, 
sideroplastic anaemia 
Infancy-childhood PUS1, YARS2 
SANDO Sensory ataxia, neuropathy, 
dysartria, ophtalmoplegia  
20–30 years POLG 
 
 
In conclusion, due to extremely variable clinical presentation, oxidative 
phosphorylation defects are suspected in patients with a) an unexplained combi-
nation of neuromuscular symptoms and/or non-neuromuscular symptoms; b) a 
progressive disease course, and c) the involvement of seemingly unrelated 
organs or tissues (Munnich and Rustin 2001). 
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2.3.5. The diagnostic criteria of MD 
Due to the extremely non-specific clinical picture, additional indications sugges-
tive of MD including characteristic laboratory, metabolic and morphological 
abnormalities are helpful in diagnosis. Screening based on the measurement of 
lactate levels in serum and cerebrospinal fluid is used for first-line diagnostis, but 
lactic acidosis may be present in only 50% of patients (Gropman 2001; Koenig 
2008). In patients with neurologic symptoms, cerebrospinal fluid lactate is 
considered to be more reliable than venous lactate (Koenig 2008). Elevated Krebs 
cycle intermediates observed in organic acid analysis and elevated alanine are the 
most widely observed metabolic changes. Lactate to pyruvate ratio is as important 
as each component individually, as a ratio greater than 20 is suggestive of a defect 
of oxydative phosporylation, whereas a ratio below 20 suggests a defect in the 
Krebs cycle (Gropman 2001). Suomalainen et al (2011) recently reported that the 
measurement of fibroblast growth factor-21 (FGF-21) concentrations in serum 
identified primary muscle-manifesting RC deficiencies in adults and children and 
might be feasible as a first-line diagnostic test for these disorders in order to 
reduce the need for muscle biopsy.  
 The most important instrumental investigations in patients with a suspected 
mitochondrial disease are brain MRI and magnet resonance spetroscopy (MRS). 
MRI is especially useful in children with nonspecific neurologic symptoms and 
subtle biochemical, biochemical and morphological abnormalities. Symmetric 
grey matter nuclei involvement may be the most predominant finding. In the 
brainstem, the periaqueductal grey matter, pons, and mesencephalon are the 
common sites of involvement. LS caused by necrosis and cavitations in the basal 
ganglia, midbrain, pons, and posterior column of the spinal cord is strongly 
suggestive of the presence of a defect in the energy-producing pathway. Puta-
minal involvement is reported to be a constant feature in LS. Other abnormalities 
where MD may be suspected are abnormal myelination and infarct-like lesions 
(Gropman 2001). The accumulation of lactate and N-acetyl-aspartate are the most 
common findings detected using MRS (Kisler et al., 2010).  
 The diagnostic information for MD is often obtained on examinations 
performed on muscle tissue. Biopsy specimens should be examined with routine 
light microscopy for structural changes, evaluated histochemically or with an 
electron microscope. One pathomorphological hallmark observed from muscle 
tissue is abnormal mitochondrial proliferation, which is seen as RRF. These 
fibres also stain strongly for succinate dehydrogenase and negatively for COX, 
which is a sign of the accumulation of mitochondria in response to a defect in 
OXPHOS. Electron microscopic study reveals intramitochondrial paracristalline 
inclusions or disrupted cristae (Gropman 2001).  
 Biochemical analysis of RC enzymes can be performed from muscle 
biopsies, cultured skin fibroblasts and blood lymphocytes if necessary. Indi-
vidual activities of the complexes I–V and the combined activities of the 
complexes I+III and II+III are measured (Finsterer 2004; Gropman 2001; Kisler 
et al., 2010).   
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 Different consensus diagnostic criteria for MD in childhood are available – 
for instance Wolfson (Nissenkorn et al., 1999), modified Walker (Bernier et al., 
2002) and Nijmegen criteria  (Morava et al., 2006; Wolf and Smeitink 2002). 
These usually score major and minor criteria based on clinical, biochemical and 
molecular findings. The Wolfson criteria are based on a classic mitochondrial 
phenotype, which is considered to be the major criterion. For definite diagnosis 
of MD, at least one of the minor criteria should be present. These minor criteria 
consist of family history and characteristic metabolic, biochemical, genetic 
(mtDNA) or pathomorphological changes observed from muscle tissue (Nis-
senkorn et al., 1999).  
 The modified Walker criteria involve the adaptation of the adult diagnostic 
criteria to children, allowing better sensitivity for the identification of MD in 
children (Bernier et al., 2002). The major criteria in this scoring system consist of 
clinical phenotype (classic syndrome or unexplained newborn, infant death) and 
the histochemical, biochemical and genetic findings in muscle tissue at a certain 
level. Minor criteria consist of the same criteria, but at a lower level (for 
example – RRF <2% of fibres) and also metabolic abnormalities. Finally patients 
are classified as definite, probable and possible MD (Bernier et al., 2002). 
 The Nijmegen criteria for MD (table 11) are more complex and involve 
detailed clinical symptoms, the results of instrumental investigations and meta-
bolic findings. All general criteria are evaluated by points – each criterion gives 
1–2 points.  
 
 




2.3.6. The epidemiology of MD 
The first epidemiological study evaluating mitochondrial abnormalities in 
children with unexplained psychomotor retardation was performed in Finland, 
where a biochemical defect of oxidative phosphorylation was found in one out 
of 5634 children (Uusimaa et al., 2000). Subsequent epidemiological investiga-
tions have not succeeded in showing such high prevalence in Sweden (Darin et 
al., 2001) and Australia (Skladal et al., 2003). A comparison of epidemiological 
data is given in table 12.  
 
 
Table 12. The prevalence of MD in childhood in different populations 




Northern Finland  
Children <18 years 
1:5634 Not calculated Uusimaa et al 2000  
Western Sweden 
Children <16 years 
1:21,000 2.8–7.6 Darin et al., 2001 
Victoria, Australia 
Children <16 years 
1:20,000 4.0–6.2 Skladal et al., 2003 
Estonia 
Life-birth prevalence 
1:20,764 1.5–11.2 Current study 
 
 
With the improving diagnostic possibilities and new phenotypes and genetic 
associations discovered, the number of MDs is rapidly growing, and it is 
estimated that the prevalence of MD in the general population is as high as one 
in 5000 (Elliott et al., 2008; Schaefer et al., 2004; Skladal et al., 2003). 
 
2.4. Urea cycle disorders 
2.4.1. An overview of UCD 
Ammonia (NH4
+) arising from amino acid metabolism is mainly detoxified in 
the liver through its conversion to urea (Zschocke and Hoffmann 2011). UC 
(figure 5) comprises six different enzymes, three of which function in the mito-
chondrial matrix: N-acetylglutamate synthase (NAGS), carbamoylphosphate 
synthetase 1 (CPS 1), ornithine transcarbamoylase (OTC). The other enzymes 
are found in cytosol – argninosuccinate synthetase (ASS), argininosuccinate 
lyase (ASL) and arginase (Nassogne et al., 2005). CPS1 catalyses the initial 
condensation of ammonia and bicarbonate. This requires activation by N-
acetylglutamate, which is itself formed by NAGS. Subsequently, carba-
moylphosphate is bound to ornithine by OTC. This results in the formation of 
citrulline, which is transported out of the mitochondrion and bound to aspartate 
by ASS. The resulting argininosuccinate is split by ASL into fumarate and 
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arginine, which is in turn hydrolysed by arginase into ornithine and urea. Urea 
is excreted and ornithine is transported back into the mitochondrion via the 









The list of UCDs is given in table 13. 
 
 
Table 13. Overview of UCD, related genes and modes of inheritance.  
*HHH syndrome– hyperammonaemia, hyperornithinaemia, homocitrullinaemia 
syndrome 
 
Enzyme Disease Gene Inheritance Phenotype 
OMIM 
CPS1 CPS1 deficiency CPS1 AR 237300 
NAGS NAGS deficiency NAGS AR 237310 
OTC OTC deficiency OTC X-linked 311250 
ASS Citrullinaemia ASS AR 215700 
ASL Argininosuccinic 
aciduria 
ASL AR 207900 




HHH syndrome* SLC25A15 AR 603861 
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Clinically, UCD may present at any age with hyperammonaemia and its neuro-
logic sequelae. The two most proximal defects (OTC and CPS1 deficiency) that 
present often with severe hyperammonaemia in the neonate have the highest risk 
for acute neurological injury (Gropman et al., 2007). The developing brain is 
more susceptible than the adult brain to the deleterious effects of ammonia. 
Hyperammonaemia causes irreversible damage to the developing brain, causing 
cognitive impairment, seizures and cerebral palsy. Children develop cortical 
atrophy and demyelination of the grey and white matter. The extent of the irrever-
sible damage depends on the maturation of the brain and on the magnitude and 
duration of hyperammonaemia. Irreversibility mainly occurs in the case of 
prolonged hyperammonaemic crises, when the blood level reaches levels between 
200 and 500μM during the first two years of life (Braissant 2010). 
 The clinical picture of arginase deficiency is different. Those patients usually 
present with spastic diplegia or quadriplegia and there is rarely hyper-
ammonaemia to the extent experienced in other UCDs. A similar clinical picture 
with evidence of pyramidal tract involvement and moderate hyperammonaemia 
is also observed in HHH syndrome (Gropman et al., 2007). 
 The prevalence of UCDs as a group in the USA is estimated to be 1:8200 
(Braissant 2010). Keskinen et al evaluated the incidence of this group of 
diseases in Finland (Keskinen et al., 2008). In the period 1998–2007 the total 
incidence of UCDs in Finland was 1:39,000, with OTC deficiency being the 
most frequent of this group of disorders, having a frequency of 1:62,000. The 
incidence of UCDs in Estonia has not been systematically evaluated (Keskinen 
et al., 2008). 
 
2.4.2. Ornithine transcarbamylase deficiency 
2.4.3. The clinical picture of OTC 
The clinical manifestations in patients with CPS, OTC, ASS and ASL deficien-
cies are virtually identical, but demonstrate great variability within and among 
these diseases (Brusilow 2001). Diseases can manifest in the neonatal period 
and be fatal, or they may appear any time thereafter with varying degrees of 
severity. Hyperammonemia is the common clinical presentation of all of these 
diseases (Brusilow 2001). Clinically, children with OTC deficiency are almost 
always born from a normal full-term pregnancy and normal labour, and 
generally there are no known prenatal or perinatal risk factors. Some days after 
birth (often 24 to 72 hours, occasionally longer), the child becomes lethargic. 
Within hours additional symptoms may develop, including vomiting, increasing 
lethargy, hypothermia and hyperventilation. The clinical symptoms are often 
misinterpreted as pulmonary disease, notwithstanding radiological findings and 
respiratory alcalosis. A workup for sepsis in such patients is unrevealing. If the 
plasma ammonium level is not measured, the infant’s death will be ascribed to 
sepsis, intracranial haemorrhage or some other disease (Brusilow 2001). If 
hyperammonaemia is detected, prompt metabolic investigations should follow. 
The biochemical hallmarks of OTC deficiency are elevated plasma ammonia, 
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glutamine and alanine, low levels of arginine and citrulline and increased 
excretion of urinary orotic acid (Bachmann 2003; Msall et al., 1984).  
 Apart from acute neonatal presentation, a late-onset beginning has been 
described in up to 44% of patients (Nassogne et al., 2005). This form of the 
disease can present from infancy up to the fourth decade (Brusilow 2001). The 
late-onset form has four different clinical presentations: hepatogastric with 
average onset at the age of 14 months; neurological disease in the form of 
chronic encephalopathy or relapsing neurological episodes (average age of on-
set 4 years); episodic psychiatric disease with average onset at the age of 8 years 
(Nassogne et al., 2005). 
 Symptoms in carrier females are variable – some are totally asymptomatic, 
while approximately 15% of others have episodes of severe hyperammonemia, 
which can lead to brain damage or even death (Yorifuji et al., 1998). More than 
80% of heterozygous females are asymptomatic, while others present symptoms 
including vomiting, lethargy, coma, ataxia, cognitive disability and death due to 
hyperammonaemia. Protein aversion is common (Balasubramaniam et al., 
2009). 
 The principles for the treatment of OTC deficiency are strict protein restric-
tion and arginine supplementation to overcome the enzymatic block. Hyper-
ammonaemic episodes are treated aggressively with drugs, promoting the 
removal of ammonia (Na-benzoate, Na-phenylbutyrate) and hemodialysis if 
necessary (Zschocke and Hoffmann 2011).  
 Precise prognosis and neurologic outcome is not straightforward, as there is 
no direct correlation between genotype, age of onset, peak ammonia level, 
imaging and/or phenotype. Normal intelligence is possible after a hyperammo-
naemic event and appears to depend on the duration of the coma (Gropman et 
al., 2007; Msall et al., 1984). 
 
 
 2.4.4. The genetics of OTC  
OTC deficiency is inherited as an X-linked semidominant trait. The OTC gene 
maps to the locus Xp21, spans 73 kb and contains 10 exons (Hata et al., 1988). 
Nearly 350 different mutations, predominantly missense mutations and small 
deletions or insertions, have been reported. Mutations in the OTC gene are 
found in about 80% of patients. It has been hypothesised that the remaining 
20% of cases may be caused by mutations in the promoter region or introns of 
the OTC gene and locus heterogeneity or copy number variants, such as micro-
deletions (Yamaguchi et al., 2006). Schelochkov et al (2009) have shown that 
15% of OTC deficiency cases have deletions identifiable by array comparative 
genomic hybridisation (aCGH) involving the OTC gene (Shchelochkov et al., 
2009).  
Like the other urea cycle enzymes, OTC gene is expressed in the liver and 
gut (Brusilow 2001). 
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3. AIMS OF THE STUDY 
 
The aims of this study were: 
1. To introduce MS/MS method for acylcarnitine analysis into clinical practice 
in Estonia. 
2. To evaluate the effectiveness of biochemical diagnosis of FAOD and to 
establish the prevalence of FAOD in Estonia. 
3. To investigate the genotype and phenotype of Estonian LCHADD patients. 
4. To evaluate the effectiveness of a diagnostic algorithm for mitochondrial 
diseases in Estonia. 
5. To establish the live-birth prevalence of childhood-onset mitochondrial 
diseases in Estonia. 
6. To characterise complexity of genetic mechanisms contributing to the 





4. MATERIAL AND METHODS 
4.1. Study subjects 
4.1.1. Patients with suspicion of FAOD 
4.1.2.1. The study group of anonymous newborns 
4.1.2.1.1. The study group of anonymous newborns tested for the presence of 
the c.1528G>C mutation 
For the NBS of PKU and hypothyreosis in Estonia, six bloodspots were ob-
tained from every newborn between 3–5 days of age. The test cards were sent to 
the Department of Genetics of Tartu University Hospitals for analysis and were 
subsequently stored there.  
 We obtained DNA from anonymous samples collected from a cohort of 1040 
anonymous newborn samples. These neonates were consecutively born in 
Estonia in January 2005. We screened these samples for the presence of the 
c.1528G>C mutation in the HADHA gene. About 90% of newborns born during 
this month throughout Estonia were covered.  
 
4.1.2.1.2. The study group of anonymous newborns tested for the presence of 
the c.1690–2A>G mutation 
Genomic DNA isolated from 59 anonymised dried bloodspots collected from 
the general Danish population was used to determine the frequency of the 
HADHA c.1690 -2A>G mutant allele.  
 
4.1.2.2. The study group of symptomatic patients 
4.1.2.2.1. The study group of symptomatic patients with suspicion of FAOD in 
the period 2004–2007  
In the years 2004–2007, the blood samples of 102 individuals were sent from 
various hospitals in Estonia to a molecular laboratory of the Department of 
Genetics of Tartu University Hospitals for the determination of both LCHAD 
and MCAD deficiency. All were molecularly tested for the common 
c.1528G>C HADHA mutation that causes LCHADD and for the common 
c.985A>C ACADM mutation that causes MCADD. In some cases, in addition to 
the molecular analysis (including heterozygotes for the c.1528G>C mutation 
found among the general population), ACP by tandem MS analysis was 
performed using dried blood spots collected on a Guthrie card at the Charité-
Virchow Klinikum (Berlin, Germany).  
 
4.1.2.2.2. The study group of symptomatic patients with clinical suspicion of 
FAOD in the period 2008–2011  
Since 2008 496 patients with clinical symptoms of FAOD were first investi-
gated by tandem MS analysis of acylcarnitines from plasma. The indication list 
for the study of plasma acylcarnitine profiles was developed and adapted from 
Duran (Duran 2003) – table 14.  
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Table 14. List of indications for plasma ACP (Duran 2003). 
 
 
If a child had at least one feature from the indication list, plasma acylcarnitine 
analysis was performed. All investigated patients were selected from two 
regional hospitals (Tartu University Hospital and Tallinn Children’s Hospital), 
which serve as reference centres for the whole of Estonia (population of about 
1.34 million).  
 
4.1.2. Patients with suspicion of MD 
All patients referred for the investigation to the departments of neonatology or 
pediatric neurology of two regional hospitals (Tartu University Hospital and 
Tallinn Children’s Hospital) were screened for the possible symptoms of MD. 
The study was performed from 2003 to 2009. The study protocol is schema-
tically illustrated in Figure 5.  
Presymptomatic indications 
 Family history 
 SIDS in family 
 Pregnancy complications 






 Elevated transaminases 
 Elevated creatine kinase activity 
 Dicarboxylic aciduria 
 Hydroxydicarboxylic aciduria 
 
Clinical indications 
 Respiratory distress 
 Lethargy  
 Coma 
 Recurrent vomiting 
 Failure to thrive 
 Apnoe 
 Muscular hypotonia 
 Bradycardia 








 Reye or Reye-like syndrome 
 Renal tubular acidosis 
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Figure 5. Diagnostic algorithm for patients referred to muscular biopsy due to suspicion 
of MD. 
   
 
Serum lactate was routinely measured in patients presenting with symptoms 
suggestive to MD. If an increased concentration was detected, lactate level was 
checked repeatedly to avoid elevations due to technical factors. If the lactate 
level was constantly above the reference range, MD was suspected and meta-
bolic and instrumental investigations were performed to establish the disease 
phenotype. If biochemical and instrumental investigations supported the 
diagnosis of MD, a muscular biopsy was performed.  
 Pathomorphological studies, including immunohistochemical and ultrastruc-
tural examinations, were performed on muscle biopsy using routine histological 
evaluation, immunohistochemistry (including cytochrome c oxidase activity, 
staining for nicotinamide adenine dinucleotide, ragged red fibres) and electron 
microscopy. If changes characteristic of MD were found, biochemical investi-
gations were carried out on muscle tissue to evaluate the function of respiratory 
chain enzyme complexes. If the dysfunction of RC complexes was diagnosed in 
muscle tissue, their activity was also in some cases evaluated in skin fibroblasts. 
Finally, molecular studies were performed. The strategy for molecular investi-
gations was based on the clinical presentation, pathomorphological findings and 
biochemical phenotype observed in muscle tissue, and the biochemical pheno-
type observed in skin fibroblasts.  
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4.1.3. Individual cases with rare metabolic diseases 
Patients with unusual presentation of metabolic diseases referred to genetic 
consultation at Tartu University Hospital and Tallinn Children’s Hospital were 
investigated and described in the framework of the current study.  
 
4.2. Methods 
4.2.1. MS/MS method for acylcarnitines 
Acylcarnitines were analysed as butylesters. Sample preparation was performed 
using standard methods (Matern 2008b). 100 μl deuterated internal standards in 
methanol were added to 20 μl of plasma. 300 μl acetonitrile was used to 
sediment plasma proteins. Samples were centrifuged at 4C for 3 minutes, and 
the supernatants were removed. After evaporation, the extracts were butylated 
using 60 μl butanol/HCl at 65°C for 15 min. The samples were dried again on a 
SpeedVac and finally dissolved in 100 μl of acetonitrile/H2O/formic acid 
(80:20:0,025, respectively). 25 μl of the samples were injected into tandem MS 
(3200 Qtrap, Applied Biosystems MDS Sciex, Canada). Acylcarnitines were 
measured as a positive precursor ion scan for the 85 Da fragment. Quanti-
fication was performed using labeled carnitine standards set B from Cambridge 
Isotopes Inc (MA, USA).  
 
 
4.2.2. Molecular analysis of HADHA gene 
4.2.2.1. DNA extraction 
Patients’ DNA was extracted from peripheral blood using the standard salting 
out method or from newborn screening test cards. DNA was extracted from a  
3 mm disc of the test card, which was soaked in 1 ml of distilled water for at 
least 2 hours, with constant vigorous swirling of the tubes. Then the supernatant 
was discarded, 100μl of methanol was added under a ventilation hood, and 
samples were incubated for 15 min at room temperature. In the next step, the 
methanol was discarded and 100μl of freshly-prepared 5mM NaOH and 20–
50μl of mineral oil was added. Then samples were incubated at 100°C for  
15 min and immediately placed on ice. The obtained DNA solution can be stored 
briefly at +4°C or at –20°C for years. This extraction method is cost-effective and 
also quite robust, as the DNA can easily be used for other PCR-based applications 
for at least 5 years (Laugesaar et al., 2010; Teek et al., 2010). 
 
4.2.2.2. The detection of mutation in the HADHA gene 
For c.1528G>C detection, a slight modification of the PCR-RFLP method and 
primers described by Den Boer et al (2002) were used. PCR was carried out in 
96-well plates with a total volume of 10 μl. We used a higher Mg2Cl con-
centration (2.5 mM) than that described in the article by den Boer et al (2002), 
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i.e. 1.5 μl of DNA solution and 0.65U HOT FIREPol® DNA Polymerase (Solis 
BioDyne, Estonia) per reaction. In addition, for test card DNAs the number of 
PCR cycles was increased from 30 to 35. The amplified 224 bp PCR products 
were directly digested in the 96-well plate after the addition of 1.2 μl of Buffer 
O and 8U of restriction enzyme PstI (Fermentas; Lithuania). The restriction 
fragments of 175 bp and 49 bp in wild-type alleles and 117 bp, 58 bp and 49 bp 
in mutant alleles were analysed on a 2% (wt/vol) agarose gel with ethidium 
bromide staining.  
 a) HADHA gene sequencing 
The 20 exons that make up the HADHA gene and nearby intronic elements were 
sequenced as described by Olpin et al (2005).  
 b) Detection of the HADHA c.1690 -2A>G mutant allele 
For detection of the HADHA c.1690 -2A>G mutant allele, the sequence analysis 
of a 355 bp PCR fragment covering exon 17 and nearby intronic elements was 
used.  
 
4.2.3. Methods used in diagnostic algorithm for MD 
Our diagnostic algorithm of MD comprised of different investigation methods: 
serum and CSF lactate concentration was measured by photometric enzymatic 
method, amino acids in bodily fluids by HPLC and organic acids by GC/MS. 
Routine instrumental investigation methods (EMG, MRI, MRS) were used. 
Also pathomorphological studies from muscle tissue and biochemical studies 
from muscle tissue and fibroblasts were performed using routine methods used 
in clinical practice. As the author of the dissertation has not participated in those 
investigations, these methods are not described. 
 
 
4.2.4. Establishment of the prevalence of FAOD in Estonia 
The estimated prevalence of FAOD is calculated on the basis of the hetero-
zygote frequency using the Hardy-Weinberg equilibrium and taking into 
account the genotyping data of Estonian patients. 
 The live-birth prevalence of FAOD was defined as the total number of cases 
with an FAOD born from 2007 to 2011, divided by the total number of live 
births in the same period. Annual live-birth data was obtained from the 
Statistical Database of Statistics Estonia, an agency of the Ministry of Finance 
of Estonia (www.stat.ee).  
 
 
4.2.5. Establishment of the live-birth prevalence  
of MD presenting in childhood in Estonia 
The live-birth prevalence of MD was defined as the total number of cases with a 
mitochondrial defect born from 2003 to 2009, divided by the total number of 
live births in the same period. Annual live-birth data was obtained from the 
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Statistical Database of Statistics Estonia, an agency of the Ministry of Finance 
of Estonia (www.stat.ee).  
 
4.2.6. Ethics 
This study was approved by the Research Ethics Committee of the University of 
Tartu. 
 The evaluation of the mutation c.1690–2A>C in HADHA gene from DNA 
isolated from  anonymised dried bloodspots collected from the general Danish 
population study was approved by the Central Denmark Regional Committee on 
Biomedical Research Ethics.  
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5. RESULTS AND DISCUSSION 
5.1. Fatty acid oxidation defects (Publication I) 
5.1.1. Results of the investigation of newborn children 
The c.1528G>C mutation is the most common LCHADD mutation in other 
European countries (Finland, Poland, The Netherlands) (den Boer et al., 2000; 
Piekutowska-Abramczuk et al., 2010; Tyni and Pihko 1999). Therefore we 
decided to study the frequency of the c.1528G>C HADHA mutation in the 
general Estonian population in order to establish a carrier frequency of the 
common LCHADD mutation and to estimate disease prevalence in Estonia.  
 For this purpose we tested 1040 anonymous Estonian neonates for the pre-
sence of the above-mentioned mutation. Six heterozygotes for the c.1528G>C 
mutation, and no c.1528G>C homozygotes, were found. To exclude the 
possible LCHADD in the patients due to a different mutation on the other allele, 
the acylcarnitine profiling of all heterozygous individuals from a newborn 
Guthrie card was performed at the Charité-Virchow Klinikum (Berlin, Ger-
many). None of the c.1528G>C heterozygotes had biochemical abnormalities 
suggestive of LCHADD. Our results showed that the frequency of hetero-
zygotes for the c.1528G>C mutation in Estonia is high – 1:173. This is similar 
to the frequency observed in Finland and Poland (Piekutowska-Abramczuk et 
al., 2010; Tyni and Pihko 1999). The comparison is given in Table 6. 
 Based on this data, the theoretical prevalence of c.1528G>C homozygotes 
calculated using the Hardy-Weinberg Equilibrium in Estonia is 1:119,700.  
 
 
5.1.2. Results of selective screening for FAOD 
5.1.2.1. The study group of symptomatic patients with suspicion of 
FAOD in the period 2004–2007 
During the period 2004–2007, biochemical investigations of FAO defects were 
not available in Estonia; therefore mutation screening for the common mutation 
in the HADHA gene was used for LCHADD diagnostics.  
 During this period, 102 individuals were molecularly tested for the 
c.1528G>C HADHA mutation. One patient was found to be homozygous and 
one heterozygous for the c.1528G>C mutation (Table 15; case 3). The homo-
zygous child presented at the age of 6 months with fatal hypoglycemia during 
intercurrent illness, and FAOD was suspected due to the characteristic clinical 
picture. The heterozygous individual was referred due to the complicated family 
history, as two of his children had died at an early age (Table 15; cases 1 and 2).  
 In retrospective molecular study we were able to specify the diagnosis in one 
family many years after the death of the sick children. Nevertheless, mutational 
analysis has some shortcomings for usage in the selective screening of 
LCHADD, as it is relatively time-consuming and expensive, and is not parti-
cularly informative. Therefore its clinical applications are limited and it is 
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generally used in case of a high suspicion of LCHADD, for instance in patients 
presenting with hypoglycemia during an intercurrent illness, Reye or Reye-like 
syndrome, SIDS or near-SIDS syndrome and complicated family history (SIDS 
in siblings or maternal HELLP syndrome). 
 
5.1.2.2. The study group of symptomatic patients with clinical 
suspicion of FAOD in the period 2008–2011 
During the period 2008–2011, a group of 496 patients were analysed by ACP 
according to the indication list given in table 14. Acylcarnitines were analysed 
from plasma in the majority of patients (426); in 70 patients ACP was per-
formed from a dried blood spot. Generally, heparinised plasma is the preferred 
material for the diagnosis of FAOD in symptomatic patients (Matern 2008a), 
and a dried blood spot is used in NBS. It is also recommended that the positive 
cases detected from the dried blood spot sample are confirmed from the plasma 
sample (Zschocke and Hoffmann 2011). 
 Out of this group, we identified two patients (table 15; cases 4 and 5) who 
had an abnormal acylcarnitine profile typical of LCHADD. The reasons for the 
referral of these patients were: recurrent vomiting, lethargy, hypoglycemia, liver 
dysfunction (table 15; case 4) and lethargy, failure to thrive, muscular hypotonia 
and slight liver dysfunction (table 15; case 5). Molecular analysis showed that 
both patients were homozygous for the c.1528G>C mutation in the HADHA 
gene.  
 Additionally, we identified one case of MCADD in a patient with borderline 
hypoglycemia, which was easily corrected by the administration of a 40% oral 
glucose solution. 
 The two LCHADD patients are the first living patients in Estonia who are 




5.1.3. Patients with LCHADD 
5.1.3.1. The clinical picture of LCHADD patients 
The clinical presentation of patients is shown in table 15. 
 
 
Table 15. The clinical presentation of LCHAD patients identified during the study. 
 
 Case 1 Case 2 Case 3 Case 4 Case 5 
Born (year) 1987 1995 2007 2009 2010 
Age at first 
presentation 
3.5 months 9 months 6 months 12 months 5 months 
Muscular 
hypotonia 







Liver disease ND +* ND + + 
Cardiomyopathy + +* ND – + 
Hypoglycemia ND +** + + – 
Lactic acidosis ND +** ND + + 















Outcome Died at the 
age of 3.5 
months 
Died at the 
age of 2 
years 7 
months 
Died at the 















ND- not detected/observed 
* diagnosed during a disease episode at the age of 14 months 
** observed during the fatal episode at the age of 2 years 7 months 
*** based on the results of the HADHA gene analysis performed on both parents 
 
 
The clinical presentations of our patients represent the severe LCHADD pheno-
type that is characteristic of patients who are homozygous for the c.1528G>C 
mutation (Olpin et al., 2005; Tyni et al., 1997). The medium age at first pre-
sentation was 7.1 months (3.5–14 months). At least three patients had 
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hypoglycemia in initial presentation, and in at least two cases hypoglycemic 
episodes prior to diagnosis were fatal (cases 2 and 3). Retrospective analysis of 
the disease histories of those two cases revealed that both patients had 
symptoms indicating LCHADD prior to the fatal episode of the disease. These 
children might not have died if early specific diagnostic possibilities and 
treatments had been available. The family history was complicated in families 1 
and 2 (Case 1 died at the age of 3.5 months due to cardiomyopathy; Case 3 had 
antenatal death and HELLP syndrome in the family history). Therefore we 
suggest that a complicated family history is an important symptom of possible 
LCHADD, and this disease should be excluded in all patients born to such 
families. We observed muscular hypotonia causing a delay in infantile motor 
development in two patients (cases 4 and 5). Therefore we assume that this is a 
very important clinical sign of LCHADD, and acylcarnitine profiling should be 
considered in every such patient in order to prevent life-threatening metabolic 
crisis. 
 During our retrospective molecular study we were able to specify the 
diagnosis in one family many years after the deaths of the sick children.  As no 
material from cases 1 and 2 were available for genetic studies, we performed 
molecular investigations of the HADHA gene in the DNA of both parents. We 
detected the c.1528G>C mutation in the father and a novel c.1690–2A>G 
mutation in the mother, which is expected to cause abnormal HADHA splicing. 
We assume that the HADHA genotype c.[1528G>C]+[ 1690–2A>G] is respon-
sible for the death of the two siblings in this family. Establishing the exact 
molecular genotype in this family enabled us to offer genetic consultation for 
the other two siblings, who were both heterozygous for the c.1528G>A 
mutation. 
 Specific biochemical investigations were only performed in cases 4 and 5. 
Urinary organic acid GC/MS analysis revealed markedly increased excretion of 
3-hydroxy dicarboxylic acids (3-OH adipic, 3-OH suberic, 3-OH sebacic, 3-OH 
dodecanedioic, 3-OH tetradecanedioic acid), with some dicarboxylic aciduria in 
both patients. Plasma acylcarnitine analysis revealed elevated C14–18 and their 










































Figure 6. The normal acylcarnitine profile from plasma (A) in comparison with that of 
the LCHADD patient (B). Diagnostic peaks of C18-OH and C18:1-OH are marked. C16-







Although the presence of 3-hydroxy-dicarboxylic acids with a chain length of 
10 to 14 carbon atoms in urine by GC/MS have been demonstrated in several 
patients (Choi et al., 2007; Hintz et al., 2002), urinary organic acid analysis is 
not completely reliable in the diagnosis of FAOD, as abnormal results can only 
be obtained during acute symptoms (Olpin et al., 2005; Roe and Coates 1995; 
Tyni and Pihko 1999). 
 Acylcarnitine profiling by tandem MS is considered to be the “cornerstone” 
in the diagnosis of FAO defects, as it is a very sensitive test for β-oxidation 
defects, and also gives information  about the type of defect (Tyni and Pihko 
1999). This method has been available in Estonia since 2008. In the last 3 years, 
two patients (cases 4 and 5) were identified using tandem MS analysis of 
plasma acylcarnitines by elevated 3-hydroxyacylcarnitines. This profile has 
been demonstrated in LCHADD patients (Choi et al., 2007), (Hintz et al., 
2002), but has been observed in patients with MTP and isolated LCKAT 
deficiency (Sander et al., 2005). Therefore the confirmation of enzymatic or 
molecular analysis is necessary after a characteristic profile is detected (Hintz et 
al., 2002; Tyni and Pihko 1999). 
  Early identification and treatment of FAOD have the potential to improve 
outcome and may be lifesaving in some cases, as 5% of SIDS incidents are 
attributable to undiagnosed FAOD (den Boer et al., 2002; Hintz et al., 2002). 
This observation is also true in our small cohort of LCHADD patients – two 
patients (cases 4 and 5) identified by acylcarnitine analysis are the first living 
patients in Estonia who are also currently undergoing treatment. Although 
mutational screening was available a few years earlier, the introduction of 
tandem MS-based acylcarnitine analysis allowed much broader recruitment of 
patients with symptoms suggestive of FAO disorders. As plasma acylcarnitine 
profiling is an informative, relatively inexpensive and rapid method that enables 
simultaneous screening for many different FAOD, the clinical indications for its 
application are much broader than the mutational analysis of the HADHA gene. 
According to our experience, the indications given by Duran (2003) are very 
practical and suitable for the selective screening of FAOD. Our experience 
shows that muscular hypotonia causing a delay in infantile motor development 
is a very important clinical sign of LCHADD, and acylcarnitine profiling should 
be considered in every such patient in order to prevent a life-threatening 
metabolic crisis. Our main goal for the future is to introduce acylcarnitine 
analysis to all newborns as a part of our national newborn screening program.  
 
5.1.3.2. The genotype of LCHADD patients 
In our relatively small patient group, we identified eight independent LCHADD 
alleles from four families. Seven of them (87.5 %) carried the c.1528G>C 
mutation, and in one allele the c.1690–2A>G mutation was found after HADHA 
gene sequencing. In conclusion, the common c.1528G>C mutation is present on 
87.5% of disease alleles in Estonian LCHADD patients. This corresponds to the 
previous observation by Ijlst et al, who detected the common mutation in 87% 
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of the HADHA gene in the cohort of 34 patients (Ijlst et al., 1996). The 
c.1528G>C mutation is the main cause of LCHADD in Finland, as all patients 
in the cohort of 28 patients were homozygous for this mutation (Tyni and Pihko 
1999).  
 The c.1690–2A>G mutation in the HADHA gene is a novel mutation. It most 
likely causes abnormal HADHA splicing, because according to the splice site 
prediction program (http://www.fruitfly.org/seq_tools/splice.html), the c.1690  
–2A>G mutation changes the splice score of the IVS16 3’ splice site from 0.97 
to 0.0 (the maximum splice score is 1.0). Unfortunately the in vivo 
consequences of the splice site mutation could not be investigated, as no cDNA 
was available from the mother and the two deceased children. The c.1690  
–2A>G mutation was not found in the 59 DNA samples collected from the 
general population (study group 4.1.2.1.2). 
 
 
5.1.4. The prevalence of FAOD 
5.1.4.1. LCHADD  
Based on heterozygote frequency and taking into account that this common 
mutation is present on 87.5% of disease alleles in our small cohort of patients, 
we calculated that the prevalence of LCHADD in Estonia is 1:91,670.  
LCHADD frequency in Estonia is comparable to that in Poland, where its 
prevalence is 1:118,336 (Piekutowska-Abramczuk et al., 2010), and higher than 
the 1:250,000 observed in Australia, Germany and the USA (Lindner et al., 
2010). In addition, the data about carrier frequency allow one to assume that 
LCHADD frequencies in Estonia and Finland are similar. 
 However, three out of five known patients were born in the period 2007–
2010, when the patient’s recruitment was wider. Therefore, we found it justified 
to calculate the live-birth prevalence for the last period 2007–2011. As there 
were 78,891 births in this period, the prevalence of LCHADD from 2007–2011 
was 1 in 26,297. As the annual birth rate in Estonia in recent years is about 
16,000, then according to live-birth prevalence, we can expect one LCHADD 
patient every 2–6 years.  
 
5.1.4.2. MCADD  
Using ACP, we evaluated the prevalence of MCADD in Estonia among patients 
in the study group with clinical symptoms suggestive of FAOD (study group 
4.1.2.2.2). We identified only one patient with the characteristic profile of 




Figure 7. Acylcarnitine profile characteristic of MCADD. The prominent peak at  
344 m/z corresponds to octanoylcarnitine (C8). 
 
 
This patient presented at the age of 2 years and 11 months due to lethargy after 
fasting for 11 hours. The child had experienced a similar episode of lethargy 6 
months before, which resolved spontaneously. Upon hospitalisation, muscular 
hypotonia, tremors, subfebrile temperature and pharyngitis were observed. As 
the laboratory analyses revealed hypoglycaemia (1.6 mmol/l), the patient was 
included in our study group. The hypoglycaemia resolved with oral admi-
nistration of a 40% glucose solution. Due to the acylcarnitine profile characte-
ristic of MCADD, molecular analysis of the ACADM gene was performed. The 
patient was homozygous for the c.985A>C mutation in the ACADM gene.  
 As the only MCAD patient identified during this study was living in Russia 
and decompensation occurred while visiting relatives in Estonia, this does not 
influence the prevalence of MCADD among Estonian patients. Lilleväli et al 
have previously shown that the carrier frequency of the c.985A>C mutation in 
the ACADM gene in Estonia is 1:220, and the frequency of possibly affected 
homozygotes is 1 in 193,000 (Lilleväli et al., 2000). As during the selective 
screening of FAOD no patients of MCADD were identified, our data support 
the genetic data and imply that MCADD is uncommon compared to LCHADD 
in Estonia. MCADD may, however, still be underdiagnosed, as patients may 
present with very mild clinical symptoms, and this was also the case with our 
patient. Therefore it is also necessary to evaluate the incidence of MCADD in 
Estonia in NBS.  
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 Although MCADD is the most frequent FAOD in several populations (table 
7) and a remarkable north-south trend is evident in the Netherlands (Derks et 
al., 2005) and in Germany (Maier et al., 2005; Sander et al., 2001), with higher 
frequency in the north, our data are not consistent with these observations. 
Controversially, a low carrier frequency for the common mutation of the 
ACADM gene has been reported in Finland. In the cohort of random DNA 
samples from 1908 subjects, a carrier frequency of 1:191 was reported, and the 
calculated frequency for c.985A>C homozygotes was 1:147,000 (Romppanen et 
al., 1998). Therefore we can conclude that the prevalence of MCADD in 
Estonia is lower than in countries of Central and Western Europe, but similar to 
that of Finland.   
 
5.1.4.3. Other FAOD  
Although ACP is informative in diagnosing several disorders of FAO, no other 
FAOD or carnitine metabolism defects were detected during our study. This is 
probably related to the small population of Estonia, the limited duration of the 
study and the rare prevalence of the other disorders. The known prevalence of 
the other enzymatic defects affecting FAO is given in table 16. The combined 
incidence of the disorders that can be diagnosed using ACP is between 1:5000 
and 1:10,000 (Rinaldo et al., 2008).   
 
 
Table 16. The prevalence of enzymatic defects of FAO and carnitine metabolism. 
 






Japan Lee et al., 2010 
CPT1 deficiency >1:250,000 United States Chace et al., 2003 
CPT2 deficiency >1:250,000 United States Chace et al., 2003 
VLCAD deficiency 1:177,000 California Feuchtbaum et al., 
2006 
SCAD deficiency 1:20,000 California Feuchtbaum et al., 
2006 




5.1.5. Follow-up of LCHADD patients 
Due to the lack of systematic studies, current treatment recommendations are 
based on expert opinion (Spiekerkoetter et al., 2010). The management guide-
lines of LCHADD patients in Estonia were adapted from the Physician’s Guide 
to the Treatment and Follow-up of Metabolic Diseases (Ogier de Baulny and 
Superti-Furga 2006). 
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 The restriction of dietary LC-FA is necessary in order to avoid long-term 
complications as peripheral neuropathy and retinopathy due to the accumulation 
of toxic acylcarnitines (Gillingham et al., 2003; Spiekerkoetter et al., 2010). 
Two patients identified during this study (case 4 and 5) started a low-fat high 
carbohydrate diet promptly after the diagnosis. Eighty percent of their energy 
intake consisted of carbohydrates, and fat, mostly given as medium chain 
triglycerides, provided 20% of their energy. It has previously been shown that 
the strict LC-FA restriction (<10%) of caloric intake is associated with near 
normal plasma long-chain hydroxyacylcarnitines (Gillingham et al., 2003). 
Slight elevation of long-chain hydroxycarnitines was still observed during 
follow-up, probably related with the not very strict LC-FA restriction allowed 
by our guidelines. 
 There is much ongoing debate regarding carnitine supplementation, with 
little data supporting either its beneficial or harmful effects (Gillingham et al., 
2003). About half of the patients treated in different European centres receive 
L-carnitine supplementation (Spiekerkoetter et al., 2009a), but carnitine should 
be avoided at a time of severe metabolic derangement (Spiekerkoetter et al., 
2009b). No deleterious effects have been recognized while using L-carnitine at 
a median dose of 75 mg/kg daily (Ogier de Baulny and Superti-Furga 2006). As 
both patients had significantly reduced free carnitine at diagnosis, we chose to 
start L-carnitine supplementation at the dosage of 50 mg/kg/day at the 
beginning of treatment, under clinical and metabolic supervision. Low free 
carnitine levels have been observed during follow-up in both of our patients and  
oral L-carnitine supplementation was administered. 
 Clinical improvement was observed shortly after treatment was started. The 
first signs of clinical improvement were increased physical activity and 
improved muscle tone. Patient 5, who had cardiomyopathy at the moment of 
diagnosis, had no signs of cardiac involvement detected through ultrasound at 
the repeat check performed two months later.  
 Emergency regimens for acute illness were made for both of the patients. 
These regimens consisted of the guidelines for home treatment, where a 25% 
oral glucose solution is provided during the acute illness in order to avoid 
metabolic decompensation. Additionally, emergency regimens provide guide-
lines for hospitalisation and hospital treatment, where a glucose infusion of 10–
12 mg/kg/min is necessary for the maintenance of normoglycaemia, and hypo-
glycemia is corrected with a glucose infusion dosage of 0.5–1 g/kg/dosi. Patient 
4 has been followed up for about two years and patient 5 for one year – they 
have been treated during an intercurrent illness according to this schedule and 
both of them have had no episodes of decompensation during the follow-up.  
 As there is no possibility for the measurement of total and free carnitine in 
Estonia, ACP is used for laboratory follow up in LCHADD patients. Minor 
changes characteristic of LCHADD observed during the follow-up allow us to 
conclude that ACP is informative in the vast majority of LCHADD cases and 
can also be used in the follow-up of LCHADD patients. 
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5.2. Mitochondrial disorders  
 
5.2.1. Results of the application of the diagnostic algorithm for MD 
(Publication II) 
Based on the preliminary biochemical, metabolic and instrumental investiga-
tions, 22 children were referred to a muscular biopsy due to suspicion of MD.  
 Pathomorphological changes characteristic or suggestive of MD were found 
in five patients (table 17). Biochemical analysis performed from the muscle 
tissue confirmed mitochondrial disease in three of them: two patients (cases 1–
2) had combined deficiency of complexes I and IV in muscle and one (case 3) 
had a complex IV deficiency caused by mutations in the SCO2 gene [synthesis 
of cytochrome c oxidase, subunit 2 formerly known as SCO cytochrome 
oxidase deficient homolog 2 (yeast)] (publication III). Two patients (cases 4–
5) had characteristic changes in muscle pathomorphology, but neither enzymatic 
analysis revealed normal activity of RC complexes, and no changes were 
identified in the mtDNA of both patients (table 17). Additionally, biochemical 
investigations performed on muscle tissue confirmed PDH deficiency in two 
patients (cases 6–7), who had no pathomorphological changes suggestive of 
MD, but whose metabolic investigations were characteristic of PDH deficiency. 
 During the study period (2003–2009), 103,821 live births were recorded in 
Estonia. Based on the data of this study, the live-birth prevalence for mito-
chondrial defects is 1 per 20,764 live births. 
 The live-birth prevalence observed in our cohort (1:20,764) correlates 
closely with the Swedish and Australian data, supporting the conclusion that 
MD has similar prevalence in different populations (Schaefer et al., 2004), but 
is lower than in Finland (Table 12). One possible explanation for the difference 
between our cohort and the Finnish cohort may be the strict pre-selection 
criteria in our cohort – in the Finnish study a muscular biopsy was performed 
routinely in patients with unexplained encephalomyopathy and myopathy. This 
strategy is, however, unavailable to us in daily clinical practice, and therefore 
the algorithm for clinical practice was developed. 
 Most of the available diagnostic schemes for mitochondrial disorders 
(Bernier et al., 2002; Morava et al., 2006; Nissenkorn et al., 1999; Wolf and 
Smeitink 2002) are useful for the evaluation of the probability of MD based on 
the pathomorphological and biochemical findings in the muscular tissue. 
Although most authors acknowledge the broad clinical spectrum of the diseases 
(Darin et al., 2001; Gropman 2001; Kisler et al., 2010), there is a shortage of 
published data about clinical criteria in patients in whom a muscular biopsy 
should be performed. Kisler et al (2010) have published a review about the 
management of MD in childhood, covering all known clinical presentations, 
diagnostic strategy and management (Kisler et al., 2010). However, since the 
measurement of respiratory chain enzymatic activity in tissue samples is not 



























































































































































































































































































































































































































































































































































































































































































































 As our algorithm (figure 5) is based on the measurement of serum lactate 
level, the actual incidence of MD in Estonia may be higher, since the normal 
lactate level may be present in 30–70% of patients (Koenig 2008). In future 
more attention should be paid to the subtle biochemical changes (elevated 
excretion of Krebs cycle metabolites and alanine in case of normal lactate level 
etc.) and clinical presentation, including the results of instrumental investi-
gations. Measurement of FGF21 (Suomalainen et al., 2011) may also be con-
sidered in future. All of our patients with enzymatically confirmed mitochond-
rial disease presented in the newborn period, and thus it is possible to conclude 
that screening for mitochondrial disorders based on serum lactic acid measure-
ment is informative in the case of the early onset of the disease. It has recently 
been shown that an elevated level of lactate was found in 87% of patients with 
neonatal onset of MD (Honzik et al., 2012).  
 
 
5.2.2. Individual cases with rare MD detected during the study 
5.2.2.1. Patients with a defect in RC 
5.2.2.1.1. Case 1 (Publication II) 
The girl was born from the mother’s third pregnancy and first delivery. Her 
birth weight was 4190 g (+1.5 SD), length 52 cm (+1.5 SD) and Apgar score 
7/8. During the first days of life transient hypoglycemia and tachypnoe were 
observed. At the age of 1 month, following a vaccination against tuberculosis 
and hepatitis B, progressive sluggishness, muscular hypotonia, feeding and 
respiratory difficulties were observed, and the child was hospitalised. Clinically 
severe muscular hypotonia and myopathic phenotype were observed. She had 
no active movements and needed supportive ventilation with continuous 
positive nasal airway pressure. Serum lactate level was constantly elevated, with 
a maximum of 9.1 mmol/l (ref. <2.6mmol/l). Electromyographic investigation 
(EMG) showed myopathic findings, whereas brain MRI showed no pathology. 
CSF lactate was 3.67 mmol/l (ref. 1.1–2.4 mmol/l). Amino acid analysis 
revealed an increased concentration of alanine – 519.6 μmol/l (ref. 130–442) 
and elevated alanine/lysine ratio ~10 (ref. <3). The urinary organic acid profile 
showed increased excretion of succinic, fumaric, glutaric and ketoglutaric acid. 
In both muscular biopsies (performed at the age of 2 months and again at the 
age of 5 years), the pathological ultrastructure of mitochondria (whorled mito-
chondria) was the most prominent finding. At the age of 2 months ca 50% of 
fibres had RRF phenotype and at the age of 5 years ca 5–6 % of fibres were 
RRF (figure 8). Many cytochrome c oxidase negative fibres were present in 
both biopsies. Biochemical investigations from muscle tissue revealed lowered 
activities of complexes I and IV (table 18). The enzymatic activities of 
respiratory chain complexes I-IV from fibroblasts were normal. The sequencing 
of POLG and DGOUK genes revealed no mutations. Mutation m.14674T>C 





Figure 8: Case 1 muscle biopsy: (A) RRF at the age of 2 months and (B) at the age of 5 
years; (C) the ultrastructure of pathological mitochondria (whorled mitochondria) in 
electron microscopic investigation. 
 
 
Clinical course: Supportive treatment for RC was initiated at the age of 1.5 
months. The treatment schedule consisted of ubiquinone 20 mg/kg/day, ribo-
flavin 10 mg/kg/day (max 200 mg per day) and L-carnitine 100 mg/kg/day. 10–
15% more calories were added to her daily diet, mostly by fat. The first active 
movements occurred at the age of 4 months. At the age of 7 months she was 
free of supportive ventilation and her physical activity gradually began to 
improve. She began to walk independently at the age of 1 year 10 months.  
 At the age of 7 years she is still on treatment supporting respiratory chain 
function (the child began to complain of muscle pain upon discontinuation). 
Clinically she has muscular hypotonia and a myopathic phenotype. She is 
slightly slower in physical activities than her age-matched mates, but her 
cognitive development is appropriate for her age.  
 Family history: elevated lactate level was detected during physical exercise 
in the patient’s mother. Therefore we performed a muscular biopsy on her. 
Pathological mitochondria were also observed in the mother, but the changes 
were different to those observed in her daughter. Mitochondrial storages 
destroying their structure were present. No typical RRF were observed, but 
regions staining similarly to RRF in trichrome stain were present in some fibres. 
The enzymatic activities of respiratory chain complexes from the muscle tissue 
were within the normal range (table 18).  Mutation m.14674T>C mt-tRNAGlu 
was also present in mt DNA in the mother. The muscular biopsy of the mother 
was performed in 2005, and at the time the mother had no muscular complaints. 
In 2010 she began to complain of episodic muscle pain related to physical 
exercise, which showed a slow progression. These complaints resolved during 
CoQ10 supplementation.    
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Table 18. Enzymatic activities of RC complexes measured from the muscle tissue of 
patients (case 1 and 2) and the mother of case 1. 
 









Case 1 4 101 48 470 
Case 2 28 51 58 118 
Mother (case 1) 107 271 1355 113 
Ref. 84–559 37–285 520–2080 45–187 
* UCS – unit of citrate synthase 
 
 
In the patient, RC deficiency was already diagnosed during the first months of 
life, but the molecular cause remained unknown for years. Although the 
m.14674T>C mt-tRNAGlu mutation was already detected in the patient’s mito-
chondrial DNA in 2008, it was considered to be a polymorphism at the time.  
As Horvath et al (2009) described, this mutation in patients with reversible 
COX deficiency myopathy is clinically similar to that of our patient; we related 
the clinical problems in the patient to this molecular change. Patients with 
homoplasmic m.14674T>C mt-tRNAGlu mutations present with clinical 
deterioration shortly after birth or within the first months of life, clinically 
characterised clinically by lactic acidosis, profound hypotonia and feeding 
difficulties. Although a remarkable recovery is observed in these patients, mild 
myopathy is present up to adulthood (Uusimaa et al., 2011). This is also the 
case with our patient – she showed a gradual improvement within the first three 
years of life, but at the age of 7 years she still has a myopathic phenotype, and 
her physical abilities are lower than those of her coevals. The treatment 
supporting mitochondrial RC function is still necessary for her, as she starts to 
complain muscle pain if treatment is discontinued. 
  Detection of molecular cause allowed genetic consultation to the mother – as 
this change is present in maternal mitochondrial DNA as well; the familial 
recurrence risk for mitochondrial myopathy is 100%. 
 
5.2.2.1.2. Case 2 (Publication II) 
The girl was born from third pregnancy and second delivery. Her birth weight 
was 3520 g (0 SD), length 50 cm (-1 SD) and Apgar score 8/9. She developed 
breathing difficulties and hypoglycaemia (s-glycose 2.4 mmol/l; ref. 2.8–4.4) on 
the third day of life. Additionally she developed lactic acidosis up to 9.7 mmol/l 
(ref. <2.6). Clinically she had muscular hypotonia and a slightly dysmorphic 
phenotype with a broad forehead, hypoplastic supraorbital ridges and down-
turned corners of the mouth. EMG showed myopathic findings. Urinary organic 
acid analysis revealed increased excretion of Krebs cycle intermediates (lactic, 
2-OH-butyric, fumaric, ketoglutaric and 4-OH-phenyllactic acid). Amino acids 
from plasma were within the reference range, but urinary amino acid analysis 
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revealed increased excretion of alanine. Lactate from CSF was 4.8 mmol/l (Ref. 
1.1–2.4). Pathomorphological examination of muscle tissue showed lipid and 
glycogen storages in muscle fibres. No RRF were present. Cytochrome c oxi-
dase activity could not be evaluated due to technical reasons. Biochemical 
analysis of muscle tissue showed decreased activity of RC complexes I and IV 
(table 18). RC activities from fibroblasts were normal. Sequencing of TK2 
genes and mutation analysis in POLG gene revealed no mutations. Also, no 
mutations were found in the mtDNA using Affimetrix Human Mitochondrial 
Resequencing Array 2.0. 
 Treatment supporting RC function was initiated from the age 7 days. Her 
treatment schedule consisted of CoQ10 (dosage 10 mg/kg/die), L-carnitine  
(100 mg/kg/die) and creatine (200 mg/kg/die). 
 Clinical course: due to breathing difficulties the child was intubated at the 
age of 4 days and tracheostomy was established at the age of 2 weeks. Although 
her muscle strength improved gradually, she has remained dependent on 
artificial ventilation and therefore is treated in the intensive care unit of the local 
hospital. At the age of 1 year she had active movements in her extremities, she 
was able to grab toys, play with them and turn to the side.  
 Although clinical features in cases 1 and 2 are similar, their molecular 
genetic cause is different as patient 2 does not have mutation m.14674T>C mt-
tRNAGlu in her mtDNA.  Genetic cause of the combined deficiency of RC 
complexes I and IV is still unknown, but patient does not have mutations in TK2 
gene related to progressive mitochondrial myopathy due to mitochondrial DNA 
depletion. Also 3 common mutations in POLG gene are excluded.  Patient 2 has 
1 variant with unknown significance in non-coding region of mtDNA and 36 
polymorphisms were detected by mitochondrial resequencing array. 
 Although the patient showed some clinical improvement during the first 
year: she had good growth, her muscle strength improved quickly and active 
movements developed, her improvement slowed down on the 2nd year of life. 
Whether it is related to the genetic cause of her disease, or to the limitations of 
her physical activity due to artificial ventilation, is still unclear.  
 
5.2.2.1.3. Case 3 (publication III) 
A boy was born in 2005 after uneventful pregnancy at 38 week of gestational 
age. His birth weight was 3040g (–1 SD), length 47 cm (–1.3 SD). At the age of 
3 weeks he was hospitalised due to the failure to thrive. Clinically he presented 
with muscular hypotonia, feeding problems (weak sucking reflex), jaundice, 
hepatomegaly and extreme apathy. Also he had abnormal shape of the skull-flat 
forehead and slight turricephaly, slightly dysmorphic facial phenotype – high 
nasal bridge, high palate and microretrognathia. Patient’s cardiac ultrasound 
showed hypertrophic cardiomyopathy. Brain MRI investigation revealed 
bilateral hyperintensity in putamen region with T2 signals consistent to the LS 




Figure 9: Brain MRI investigation of the patient at the age of 7 weeks. Note bilateral 




EMG investigation revealed fibrillations in the muscles of the upper and lower 
limbs. No response was registered in the evaluation of motor and sensory 
nerves. Lactate in serum and cerebrospinal fluid was elevated up to 4.2 mmol/l 
and 3.8 mmol/l respectively (ref. <2.9 mmol/l). The serum amino acid profile 
(including alanine) was normal. Urinary organic acid analysis by GC/MS 
revealed elevated excretion of mitochondrial metabolites: pyruvate, malate, 2-
hydroxy-glutaric acid, ketoglutaric acid and citric acid. These metabolites were 
not quantified, but their excretion is normally virtually undetectable.  
 Routine histological examination of this patient’s muscle biopsies revealed a 
variation in muscle fibres. Muscle enzyme histochemistry showed normal 
checkerboard staining for NADH, while there was no detectable cytochrome c 
oxidase activity at all. No RRFs were found. Electron-microscopic evaluation 
showed enlarged and irregularly shaped mitochondria with an electron-dense 
matrix as well as hypertrophic mitochondria with a pale matrix and granular 
deposits. 
 RC enzyme activities were measured in the patient’s muscle and fibroblasts. 
The studies showed severely reduced cytochrome c oxidase activity and mildly 
reduced activity for complex I in the muscle and reduced cytochrome c oxidase 
activity in this patient’s fibroblasts. As both parents had mild mental retar-
dation, we performed RC enzyme activity measurements on them too. Normal 
results were observed. All results are given in Table 19.  
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The patient (case 3) Skeletal muscle 115 (520–2080) 42 (84–273) 
 fibroblasts 477 (680–1190) 158 (100–310) 
The mother fibroblasts 721 (680–1190) 949 (262–973) 
The father fibroblasts 810 (680–1190) 797 (262–973) 
* UCS – unit of citrate synthase 
 
 
During molecular genetic studies, four genes associated with cytochrome c oxi-
dase deficiency (SURF1, SCO1, SCO2, COX10) were sequenced in the patient. 
A c.418G>A heterozygous mutation (leading to a p.E140K) in exon 2 and 
heterozygous insertion of 19 basepairs at position 17 (c.17INS19bp, leading to a 
truncated protein) was detected in the coding region of the synthesis of the 
cytochrome c oxidase 2 (SCO2) gene by sequence analysis.  
 Treatment to support mitochondrial energy production (ubiquinone 5 mg/kg/ 
day; thiamine 150 mg/day; L-carnitine 50 mg/kg/day) was initiated at the age of 
6 weeks. Despite the treatment, the child’s condition worsened rapidly: 
stridorous breathing was observed from the age of 8 weeks, and muscular 
hypotonia and feeding difficulties worsened. The patient died at the age of 13 
weeks due to respiratory insufficiency. 
 Family history: both parents had mild mental retardation. His father was 
found to be a heterozygous carrier of the c.418G>A mutation and his mother 
was a heterozygous carrier of the c.17INS19bp mutation in the SCO2 gene.  
 MD in patient 3 was caused by the compound heterozygosity of mutations in 
SCO2 gene. This gene encodes a 266 amino acid protein, which is involved in 
copper supply for the assembly of cytochrome c oxidase. Mutations in this gene 
have been reported in patients with fatal infantile cardioencephalomyopathy. At 
least 26 patients, are described and all of them have been associated with 
1541G>A (E140K), which is the missense mutation probably affecting protein 
stability (Bohm et al., 2006; Jaksch et al., 2001a; Jaksch et al., 2000; Knuf et 
al., 2007; Leary et al., 2006; Papadopoulou et al., 1999; Sacconi et al., 2003; 
Salviati et al., 2002; Tarnopolsky et al., 2004; Verdijk et al., 2008; Vesela et 
al., 2004). The other eleven described mutations in the SCO2 gene result in a 
premature stop codon, deletions or insertions with a resultant frameshift and 
therefore have more serious deleterious structural consequences for the protein 
product (Bohm et al., 2006; Jaksch et al., 2000; Knuf et al., 2007; Leary et al., 
2006; Papadopoulou et al., 1999; Salviati et al., 2002; Tarnopolsky et al., 2004; 
Verdijk et al., 2008). Patients who are homozygous for the E140K mutation 
have a milder phenotype with delayed age of onset and a more prolonged course 
of disease compared to compound heterozygotes (Tay et al., 2004; Verdijk et 
al., 2008).  The c.418G>A mutation in homozygous or heterozygous state is 
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associated with all previously published cases, but the c.17INS19bp mutation) 
has not previously been described. The novel c.17INS19bp mutation in exon 2 
of this gene in our patient leads to the truncated protein, explaining our patient’s 
severe clinical course.  
 In patients with SCO2 gene mutations, skeletal and cardiac muscle shows a 
severe COX deficiency (Leary et al., 2006; Verdijk et al., 2008), whereas skin 
fibroblasts exhibit a relatively high residual enzyme activity, despite fact that  
this gene is ubiquitously expressed (Bohm et al., 2006; Jaksch et al., 2001b). 
COX activity in our patient’s muscle was very low, and significantly higher in 
fibroblasts (see Table 19), supporting this observation. 
 Reduced complex I activity in muscle is unusual in patients with SCO2 gene 
defects. It is likely that the complex I deficiency is secondary to the complex IV 
deficiency, as the secondary deficiencies have earlier been described for other 
complexes (Lenaz et al., 2006). The mechanism behind this remains specula-
0tive; perhaps it has something to do with the supercomplex formation that has 
been shown to occur (Lenaz et al., 2006). Perhaps the lack of complex IV 
prevents the formation of supercomplexes, which destabilises complex I, re-
sulting in reduced complex I activity in muscle. 
 
5.2.2.2. Patients with PDH deficiency 
5.2.2.2.1. Case 6  
The girl was born preterm on the 36th week of pregnancy in 2003. Her birth 
weight was 2219 g (–1 SD), length 44 cm (–2 SD) and head circumference 32 cm 
(–1 SD). Her Apgar score was 7/7. Due to poor neonatal adaptation, the patient 
was hospitalised to the department of neonatology. At the age of 2 weeks, a 
congenital brain anomaly was diagnosed – she had periventricular cysts, agenesis 
of the corpus callosum and dysmyelinisation. Elevated lactate level (up to  
6.6 mmol/l; ref. <2.9 mmol/l) was observed. Metabolic studies revealed a high 
blood level of alanine – 1672 μmol/l (ref. 150–600 μmol/l) – and elevated urinary 
excretion of lactate and pyruvate. PDH deficiency was suspected but not con-
firmed at the time, as the family moved away from Estonia. 
 At the next referral, at the age of 6 years, she presented with poor growth – 
weight 10 kg (–4.5 SD), height 100 cm (–4.5 SD) and head circumference  
41.5 cm (–6.5 SD). She has spastic tetraplegia with multiple contractures, a con-
vergent strabismus and dysmorphic phenotype with upward-slanting palpebral 
fissures, a high palate, a small mandible and dysmorphic ears. Her psychomotor 
development corresponded to the age of 1–2 months. Investigations to confirm 
PDH deficiency in the patient were performed. The PDH complex activity from 
fibroblasts was decreased – 4.5 mU/UCS (ref. 9.7–36). Molecular genetic ana-
lysis revealed heterozygous change c. 904C>T (p.R302C) in the PDHA1 gene.  
 Due to the late diagnosis, specific treatment to overcome metabolic blockage 
was not indicated for the patient, but thiamine (50–500 mg/day) was advised as 
a cofactor of the PDH complex. 
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5.2.2.2.2. Case 7 
The girl was born in 2005. Foetal hydrocephaly was diagnosed on the 33rd 
week of gestation. Intrauterine growth retardation and oligohydramnion were 
also observed at that stage of pregnancy. The child was born preterm on the 35th 
week of gestation. Her birth weight was 1782 (–2SD), length 39 cm (<–2 SD) 
and head circumference 29.5 cm (<–2SD). A congenital brain anomaly was 
confirmed post-natally – in addition to the hydrocephaly, the patient also had a 
hypoplastic corpus callosum. She had a dysmorphic phenotype at birth with 
dysmorphic ears, downward-slanting palpebral fissures, exophthalmus, a long 
smooth philtrum and microretrognathia. On the day 5 rapid deterioration was 
observed, with lactic acidemia up to 10.6 mmol/l (ref. <2.4) and elevated lactate 
concentration in CSF up to 13 mmol/l (ref. <1.6). The amino acid profile from 
serum, CSF and urine revealed elevated proline and alanine in all samples. 
Organic acid analysis by GC/MS from serum and urine revealed elevated lactate 
and pyruvate in both samples. The lactate/pyruvate ratio in serum was low (3.5; 
ref.10–20). 
 The enzymatic study from muscle revealed lowered PDH complex activity – 
4 mU/UCS (ref. 28–89). The PDH complex activity from skin fibroblasts was in 
the lower reference range – 9.6 mU/UCS (ref. 9.7). Pathogenic mutation 
c.904C>T (p.R302C) was heterozygously detected in exon 10 of the PDHA1 
gene through sequence analysis. 
 Treatment with thiamine as the cofactor for PHD complex was initiated at 
the age of 2 weeks, with a dosage of 500 mg daily. In addition, a ketogenic diet 
was introduced to overcome metabolic block and provide energy. The patient’s 
ketogenic diet consisted of fat, which provides up to 80% of daily calories. The 
administration of carbohydrates was restricted.  
 Clinical course: the implemented treatment gave good control over bio-
chemical pathology in the patient – the serum lactate level dropped promptly 
after the ketogenic diet was started. Despite the good metabolic control, the 
patient’s clinical condition gradually worsened: at the age of 2 months seizures 
developed, and optic atrophy was diagnosed. The patient had severely retarded 
physical and psychomotor development, and she died at the age of 2.5 years. 
Autopsy revealed generalised brain atrophy. 
 Both patients with PDH complex deficiency had the same PDHA1 genotype. 
Although the clinical course of case 7 was more severe, the cardinal clinical 
features such as congenital brain anomalies and poor growth overlapped.  
 Codon 302 is a hot spot for mutations in the PDHA1 gene, as it contains the 
highly mutagenic GpG dinucleotide (Otero et al., 1998). The mutations in this 
codon are responsible for a large number of cases in females (Lissens et al., 
2000). It has previously been estimated that mutation c.904C>T may result in 
complete inactivation of the E1α enzyme (Otero et al., 1998). Our case 7 is rare 
and represents a unique clinical presentation, as antenatal onset of PDH 
complex deficiency has been reported infrequently (Otero et al., 1998; Ro-
binson et al., 2001; Zand et al., 2003; Tamaru et al., 2012; Wada et al., 2004). 
The c.904C>T mutation has previously been reported by Otero et al in a girl 
73 
who first presented with ventriculomegaly/hydrocephalus at 32 weeks of 
gestation (Otero et al., 1998). 
 The brain involvement is a cardinal feature of PDH complex deficiency. 
Two mechanisms have been related to neurological damage. The first is the lack 
of thiamine during the early stages of embryonic development – this causes 
energy deficiency in early embryogenesis, when neuronal proliferation and mig-
ration require a great amount of energy (Barnerias et al., 2010). Clastic brain 




5.3. Individual cases detected during selective metabolic 
screening in Estonia 
During the study period (2007–2011), the author of this study participated in the 
management of patients with inherited metabolic diseases from other groups, 
and is the co-author of publications dealing with the clinical diagnosis and 
treatment of classical galactosemia (Krabbi et al., 2011; Õunap et al., 2010) and 
the establishment of the live-birth prevalence of mucopolysaccharidoses in 
Estonia (Krabbi et al 2012). 
 As a part of this study, an 8.5-year-old girl with mental retardation, epilepsy, 
and some evidence of OTC deficiency was studied in order to establish the 
mechanisms of disease manifestation and the role of a defective urea cycle 
pathway in the pathogenesis of the disease. 
 
 
5.3.1. Case report – OTC deficiency (Publication IV) 
The girl was born in 2000 from the mother’s third pregnancy and third delivery.  
Her birth weight was 3128 g (–1 SD), length 48 cm (–1.5 SD), and her Apgar 
score was 8/8. On day 2 she was admitted to the intensive care unit due to 
breathing difficulties and hypoglycaemia, and meconium aspiration was 
diagnosed. Episodic hypoglycemia was present during the first 3 weeks of life. 
Specific metabolic investigations were not performed in the newborn period. At 
the age of 2 months, during an episode of acute bronchitis, hepatomegaly was 
observed. EEG showed nonspecific paroxysmal activity, and treatment with 
phenobarbital was started. Ammonia was first increased, i.e. 90 μmol/l (ref.  
<48 μmol/l), at the age of 3 months. The first signs of developmental problems 
were noticed at the age of 6 months, and at 9 months psychomotor retardation 
was diagnosed. At the age of 9 months a high level of blood ammonia was 
detected – 297 μmol/l (ref. <48). Amino acid analysis showed no detectable 
citrulline in serum, and in urinary organic acid GC/MS analysis a slightly 
elevated excretion of orotic acid (47.7 μmol/g creatinine; ref. 1.7–35) was 
observed. Citrulline in serum was constantly low during the first 2 years of life 
(between 0 and 18 μmol/l; ref. 8–52). The highest glutamine level in serum was 
74 
1951 μmol/l (ref. 350–720) at the age of 2 years. Thereafter, an allopurinol 
loading test was performed in the Charité-Virchow Klinikum (Berlin, Germa-
ny). This test showed a significant increase in the excretion of orotic acid (3– 
4 times over the upper normal limit 12–24 hours after loading). Based on the 
metabolic investigations, this girl was suspected to be affected with a mild form 
of OTC deficiency. The treatment with oral citrulline (5g/day) and a low protein 
diet was initiated at the age of 2 years. Since that age all metabolic charac-
teristics (ammonia and amino acids) were in the normal range.  
 At the age of 12 months she had the first generalized seizures. Her EEG 
showed generalized complexes of spike waves, and her brain MRI showed 
bilateral white matter damage in the periventricular region. Treatment with 
carbamazepine was initiated (20mg/kg/day) and continued alongside a low 
protein diet and citrulline.    
 At the age of 7.5 years she was investigated at Tartu University Hospital, as 
despite the normal ammonia level and antiepileptic treatment, the patient’s 
seizure control was poor. Our clinical evaluation revealed short stature – her 
height was 111 cm (–3 SD), weight 19 kg (–2 SD) and OFC 48.5 cm (–2 SD), 
and she had developmental delay. In addition, she had slightly upward-slanting 
eyes, widely spaced teeth, a high-arched palate, low set and posteriorly rotated 
dysmorphic ears, many pigmented naevi and a large (10x10x10cm) depig-
mented area in the upper spinal region. Anticonvulsive treatment was changed 
to lamotrigine (7 mg/kg/day), and in addition treatment with sodium 
phenylbutyrate (Ammonaps) was initiated (395mg/kg/day) for a period of one 
month, with a positive effect on seizure control.  
One year later, at the age of 8.5 years, she was readmitted to hospital. Her 
height remained low (–3 SD), and moderate MR was diagnosed. Neuro-
psychological evaluation with a Kaufman ABC test revealed impaired abilities 
in all areas. She had a more pronounced attention deficit, difficulties in exer-
cises demanding analysis and synthesis, and limited short-term memory. She 
could read simple words, but she did not know numbers. She was able to cope 
in daily activities (walking, dressing and eating). In addition to her facial dys-
morphy and skin pigmentation anomalies, the brain MRI showed partial 
agenesis of the corpus callosum and bilateral white matter damage in the 
periventricular region. Additional investigations were performed to establish 
genetic etiology.  
 Molecular and cytogenetic investigation of the patient gave the following 
results: 
 (1) Bidirectional sequencing of all 10 coding exons of the OTC gene 
including intron-exon boundaries was performed using the ABI PRISM 3100 
Genetic Analyzer, but no genetic variations within coding regions were 
identified. 
 (2) Standard G-banding cytogenetic analysis was performed on peripheral 
blood lymphocytes using the standard methods, and this showed an abnormal 
karyotype 46,X,del(X)(p11). Therefore, Turner syndrome was diagnosed in the 
patient due to the loss of the short arm of the X chromosome (figure 10). 
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Figure 10. X chromosome of the patient with karyotype 46,X,del(X)(p11). 
 
 
(3) Whole genome karyotyping analysis using Human CytoSNP-12 BeadChips 
(Illumina Inc., San Diego, USA) confirmed the deletion of the whole short arm 
of the X chromosome. The deletion involved the Xp22.33-p11.1 region, and the 
borders of the deletion were found to be the following: 1–56,975,659 bp (NCBI 
build 36). The data was analysed using Illumina BeadStudio v3.1 and 
QuantiSNP v1.1 software (Colella et al., 2007)  
 (4) For the evaluation of the X-inactivation status, the androgen receptor 
(AR) (CAG)n and fragile X mental retardation 1 (FMR1) (CGG)n variable 
repeat region was examined. X-chromosome inactivation (XCI) pattern was 
determined by comparative quantitative detection of fluorescent-labeled PCR 
products using intact and methylation-sensitive restriction enzyme HpaII-
digested (Bolduc et al., 2008) and HhaI-digested DNA templates respectively. 
FMR1 PCR was performed using the FMR1 sizing PCR Set (Abbot Molecular, 
Illinois, USA) in accordance with the manufacturer’s protocol. Amplicon size 
and inactivation ratios were determined via electrophoresis on an ABI 3130XL 
Genetic Analyzer (PE Applied Biosystems) and analysed using GeneScan 4.0 
software (PE Applied Biosystems). The XCI study showed that the aberrant X 
chromosome was completely skewed in our patient (figure 11). 
 
                        
Figure 11. Results of the FMR1 methylation assay. A Undigested DNA of the patient. 
B DNA of the patient predigested with HhaI, showing an extremely skewed X-
inactivation pattern. 
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Our patient presented relatively non-specific symptoms in the newborn period, 
but later developed psychomotor retardation and seizures. Based on biochemical 
abnormalities, OTC deficiency was suspected, and corresponding treatment was 
started. Sequencing of the OTC gene was performed for final confirmation of 
the diagnosis in the patient. However, no pathogenic change was found in the 
OTC gene, and therefore further cytogenetic and molecular studies were in-
dicated to explain the biochemical changes observed in the patient. As a result, 
deletion of the whole short arm of the X chromosome and completely skewed 
X-inactivation were detected. 
 Females with partial deletions of the short arm of the X chromosome have 
variable phenotypes, but MR rarely occurs (Lachlan et al., 2006; Schinzel 
2001). There are a few reported cases with small deletions located in Xp22 that 
had MR or developmental delay and/or autistic features (Chocholska et al., 
2006; Lachlan et al., 2006; Puusepp et al., 2008; Shinawi et al., 2009; Thomas 
and Huson 2001). The haploinsufficiency of deleted genes that escape X-in-
activation may explain the occurrence of autism and developmental delay in the 
previously described cases (Shinawi et al., 2009). 
 Lachlan et al (2006) have shown that if the breakpoint of an X chromosome 
deletion is proximal to Xp.22.3, there is a non-random X-inactivation, with the 
deleted X being preferentially inactivated. XCI study of our patient also showed 
a completely skewed X-inactivation. The variability in the phenotype associated 
with Xp deletions can be explained by different mechanisms. A mosaicism for a 
normal cell line in other tissues that are not routinely tested by cytogenetic 
methods can be present (Thomas and Huson 2001). Unfortunately, it was not 
possible to perform karyotyping of skin fibroblasts (normal skin and depig-
mented areas) from our patient. The degree of expression of genes that escape 
inactivation from the inactive X chromosome is variable among different fe-
males (Carrel and Willard 2005), and the degree of skewed X-inactivation can 
vary in different tissues (Sharp et al., 2000). 
 The first cytological demonstration of cellular mosaicism in an obligate 
heterozygote of OTC was provided by Ricciuti et al (1976). The authors stated 
that the patchy distribution of OTC-positive cells within the liver provided an 
explanation both for the marked variation in OTC activity observed in different 
heterozygous females and for variable OTC activities in repeated biopsies from 
the same patient. The X-inactivation of a manifesting female with OTC defi-
ciency has previously been studied by Yorifuji et al (1998), who performed an 
AR assay using genomic DNA extracted from liver samples to study the 
skewing of the X chromosome. The results were compared with residual 
enzyme activity. A close correlation was observed, and the authors stated that 
residual enzyme activity is actually determined by the X-inactivation status in 
the liver. Unfortunately, no liver sample was available from our patient. We 
realise that our studies are insufficient to draw a correlation between X-in-
activation and the severity of clinical manifestations, but they shed some light 
on the complexity of the genetic mechanisms that are sometimes involved in the 
manifestation of genetic disorders. 
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 As our patient has MR and epilepsy, the question arises whether the patient has 
any other symptoms of haploinsufficiency in the genes located in the deleted region. 
At least 22 genes are related to MR, and some of these are also connected to 
seizures, according to the OMIM database (http://www.ncbi.nlm.nih.gov/omim/). 
These genes may contribute to the cognitive problems and epilepsy observed in 
our patient. Another possible cause for her symptoms is an encephalopathy due 
to hyperammonemic crises in infancy and childhood. 
 The characterisation of the precise nature of the genetic mechanisms in-
volved in the presentation of the X-linked disorder in the patient not only 
enabled us to offer the family an accurate genetic consultation, but also made 
possible better future surveillance. Due to the presence of Turner syndrome, 
treatment with growth hormone was considered. 
 In conclusion, we hope that this case report will contribute to the under-
standing of the underlying genetic factors of the manifestation of X-linked 





1.   We have successfully introduced acylcarnitine analysis, which is a rapid, 
informative method for the diagnosis of FAOD that enables the simulta-
neous diagnosis of different disorders affecting FAO from the same sample, 
into the clinical practice in Estonia. This has been potentially lifesaving for 
3 patients identified during this study.  
 
2.  The clinical criteria developed and used in our study are effective, practical 
and suitable for the selective screening of FAOD in Estonia. 
a) LCHADD is the most prevalent FAOD in Estonia, with a prevalence of 
1:91,670. The frequency of heterozygotes for the common mutation 
causing LCHADD in Estonia is 1:173, which is comparable to the 
prevalence in the other countries in the Baltic Sea region.  
b) The results of our selective screening of MCADD correspond to the 
genetic data from Lilleväli et al (2000) that MCADD in Estonia is rare 
compared to other European countries.  
c) No other FAOD or carnitine metabolism defects were detected during 
our study. This is probably related to the small population of Estonia, 
the limited duration of the study and the rare prevalence of the other 
disorders. 
 
3.  During our study five patients with LCHADD from four families were 
diagnosed.  
a) Seven out of eight independent LCHADD alleles (87.5 %) carried the 
most common c.1528G>C mutation in the HADHA gene.  
b) In one allele a novel c.1690–2A>G mutation was found. The mutation 
causes abnormal HADHA splicing and is associated with the classical 
disease phenotype.  
c) The clinical presentations of our LCHADD patients represent the severe 
phenotype characteristic of patients who are homozygous for the 
c.1528G>C mutation. The medium age at first presentation was 7.1 
months (3.5–14 months). At least three patients had hypoglycemia in 
initial presentation, and in two of them hypoglycemic episodes prior to 
diagnosis were fatal. 
 
4.   Our algorithm for identifying patients with MD is informative in diagnosing 
the cases presenting with elevated lactate. The vast majority of neonatal and 
infantile onset cases are identified using this algorithm.  
 
5.   Based on the data using in this study, the live-birth prevalence of MD is 1 in 
20,764 live births. The live-birth prevalence observed in our cohort corre-
lates well with the Swedish and Australian data, supporting the conclusion 
that MD has a similar prevalence in different populations. 
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6.   The detailed description of three patients with RC defects, two patients with 
PDH deficiency and one patient with OTC deficiency are given. We would 
like to point out the following: 
a) The novel c.17INS19bp mutation in exon 2 of the SCO2 gene was 
identified in one patient with reduced activity of IV of the RC. This 
mutation leads to truncated protein and is associated with the clinical 
course that is fatal at an early age.  
b) Patients with homoplasmic mutation m.14674T>C mt-tRNAGlu in 
mtDNA present in infancy with severe myopathy, which improves with 
age, but these children and adults may still need treatment supporting 
muscular energy metabolism. 
c) Both patients with PDH complex deficiency had the same PDHA1 
genotype – heterozygous mutation c.904C>T. Although the clinical 
course of case 7 was more severe, the cardinal clinical features, such as 
congenital brain anomalies and poor growth, overlapped.  
d) We described a patient with mental retardation, epilepsy, and some 
evidence of reduced OTC activity, but with no mutation identified in 
OTC gene sequencing. Cytogenetic analysis and molecular karyotyping 
using SNP array revealed a deletion of the whole short arm of the X 
chromosome (Xp22.33-p11.1). Inactivation studies also revealed 
completely skewed X-inactivation. Complex mechanisms such as large 
deletions on the X-chromosome, skewing of X-inactivation in different 
tissues and at different ages contribute to the manifestation of X-linked 
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SUMMARY IN ESTONIAN 
 
Pärilike ainevahetushaiguste haiguste valikskriining Eestis:  
uute diagnostikameetodite rakendamine 
Pärilikud ainevahetushaigused on organismi biokeemilise tasakaalu häired, 
mida põhjustavad geenimutatsioonid. Paljud nendest haigustest avalduvad vast-
sündinu- või imikueas, kuid kiiresti suureneb hilisemas vanuses diagnoositavate 
pärilike ainevahetushaiguste hulk, kaasaarvatud täiskasvanul avalduvate haigus-
vormide hulk. Hetkel on teada üle 700 päriliku ainevahetushaiguse. Vaatamata 
sellele, et iga üksiku haiguse esinemine on üliharuldane, on nende haiguste 
summaarne esinemissagedus märkimisväärne – hinnanguliselt 1:2500 vast-
sündinu kohta. 
 Patofüsioloogia alusel jaotatakse pärilikud ainevahetushaigused kolme 
gruppi: a) ladestushaigused, mille korral on häiritud kompleksmolekulide kata-
bolism, põhjustades laguproduktide ladestumise rakusiseselt; b) intoksikatsiooni 
tüüpi haigused, mille korral kuhjub puuduliku ensüümreaktsiooni substraat, 
põhjustades intoksikatsiooni; c) energia defitsiidi tüüpi haigused, mille korral 
on häire organismi energiatootmises osalevates protsessides. Viimasesse gruppi 
kuuluvad teiste hulgas rasvhapete oksüdatsioonidefektid, häired trikarboksüül-
hapete tsüklis ja mitokondriaalse hingamisahela ensüümdefektid. 
 Rasvhapped on organismi olulisim energiaallikas, tagades kuni 80% orga-
nismi energiavajadusest. Rasvhapete metabolismi põhirada organismis on β-
oksüdatsioon, mille käigus lühendatakse triglütseriidis olev pika ahelaga rasv-
hape 2-süsinikuliste jääkide võrra järk-järgult keskmise ja lühikese ahelaga 
rasvhapeteks. Vabanev atsetüül-koensüüm A siseneb trikarboksüülhapete tsük-
lisse. Ensüümdefektid võivad mõjutada rasvhapete metabolismi kõigil tase-
metel – teada on pika, keskmise ja lühikese ahelaga rasvhapete oksüdatsiooni 
defektid.  
 Rasvhapete oksüdatsiooni defektid põhjustavad patsientidel Reye’ sünd-
roomi sarnast kliinilist pilti, mis avaldub hüpoketootilise hüpoglükeemiana, 
maksa funktsioonihäire ja lihaskahjustusena. Haigushoog vallandub kataboolses 
seisundis, sageli kaasuva üldhaigestumise foonil, ning avaldub tihti vast-
sündinu- või imikueas. Esmane haigusepisood on sageli letaalne.  
 Igale β-oksüdatsiooni defektile on iseloomulik spetsiifilise süsinikuahela-
pikkusega atsüül-CoA akumuleerumine. Need metaboliidid moodustavad karnitii-
nestrid, mida on võimalik määrata atsüülkarnitiinide tandemmass-spektromeet-
rilisel analüüsil. Sellel metoodikal teostatud analüüs on korraga informatiivne 
kõigi rasvhapete oksüdatsiooni defektide ja karnitiini ainevahetushäirete suhtes. 
Atsüülkarnitiinide analüüsil tuvastatud diagnoos kinnitatakse vastaval ensüüm-
analüüsil ja/või vastavat ensüümi kodeeriva geeni analüüsil. 
 Mitokondriaalsed haigused on haigused, mis haaravad ensüüme või ensüüm-
komplekse, mis osalevad otseselt keemilise energia tootmises oksüdatiivse 
fosforüülimise protsessis. Neid haigusi põhjustavad mutatsioonid mito-
kondriaalses DNAs (mtDNA) või rakutuumas asuvates geenides. Oksüdatiivse 
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fosforüülimise defekt võib esineda igal patsiendil, kellel on ebaselge etioloo-
giaga neuromuskulaarse haiguse ja/või mitte neuromuskulaarse haiguse sümp-
tomid. Nende haiguste kliiniline pilt on erakordselt mitmekülgne ning erinevate 
haigusvormide kliiniline pilt võib kattuda. Mitokondriaalne düsfunktsioon män-
gib rolli ka mõnede „tavaliste“ haiguste patogeneesis – näiteks neurodegene-
ratiivsete haigusete, kardiovaskulaarsete haigusete, diabeedi ja vähi pato-
geneesis. 
 Kuna mitokondriaalsete haiguste kliiniline pilt on äärmiselt mittespetsii-
filine, põhineb nende haiguste diagnostika suures osas iseloomulikele labora-
toorsetele, metaboolsetele ja morfoloogilistele muutustele. Esmaseks biokeemi-
liseks markeriks on laktaaditaseme tõus veres, kuid märkimisväärsel osal 
patsientidest (kuni 50%) võib vere laktaadisisaldus olla normikohane. Mito-
kondriaalse energia tootmise defitsiidile viitavad veel Krebsi tsükli vahemeta-
boliitide erituse suurenemine uriiniga ning alaniini sisalduse suurenemine veres. 
Iseloomulike morfoloogiliste muutuste hindamine on kõige olulisem aju- ja 
lihaskoes. Ajukoes esinevate muutuste tuvastamine on võimalik aju magnet-
resonantstomograafial ning spektroskoopial, kus tüüpilisimaks muutuseks on 
hallaine tuumade sümmeetriline kahjustus ning laktaadi ja N-atsetüülaspartaadi 
akumuleerumine ajukoes. Lihaskoes esinevate patomorfoloogiliste muutuste 
olemasolu on mitokondriaalse haiguse diagnostikas määrava tähtsusega. Sage-
dasimateks muutusteks on mitokondrite patoloogilisele proliferatsioonile viita-
vad muutused ning elektronmikroskoopiliselt määratavad mitokondrite struktuuri 
muutused. Reeglina toimub lihasbiopsia materjalil ka hingamisahela enüüm-
komplekside aktiivsuse määramine ning sageli teostatakse ka molekulaar-
geneetilised analüüsid diagnoosi lõplikuks kinnitamiseks. 
 
Uurimistöö eesmärgid:  
1) atsüülkarnitiinide tandemmass-spektromeertilise metoodika rakendamine 
kliinilisse praktikasse Eestis; 
2) rasvhapete β-oksüdatsioonidefektide biokeemilise diagnostika efektiivsuse 
hindamine ning nende haiguste esinemissageduse välja selgitamine Eestis;  
3) pika ahelaga hüdroksüatsüül-CoA dehüdrogenaasi (LCHAD) defitsiidi  
genotüübi ja fenotüübi kirjeldamine Eesti patsientidel;  
4) mitokondriaalsete haiguste diagnostilise algoritmi efektiivsuse hindamine;  
5) mitokondriaalsete haiguste esinemissageduse kindlaks tegemine Eestis;  
6) harvaesinevate pärilike ainevahetushaiguste kirjeldamine. 
 
 
Materjal ja meetodid 
Rasvhapete oksüdatsiooni defektide esinemissagedust hinnati kahes grupis, 
millest kumbki jagunes kaheks alagrupiks. Esimene grupp oli asümptomaatiliste 
vastsündinute grupp, kellel hinnati LCHAD defitsiidiga seotud geenimuutuste 
esinemist HADHA geenil. Selle grupi esimese alagrupi moodustasid 1040 
anonüümset Eesti vastsündinut, kellel analüüsiti HADHA geeni põhimutatsiooni 
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esinemist ja teise alagrupi moodustasid 59 anonüümset Taani vastsündinut, 
kellel uuriti antud töö käigus kirjeldatud uusmutatsiooni c.1690 -2A>G esine-
mist. Teise grupi moodustasid patsiendid, kellel esines rasvhapete oksüdatsiooni 
defektidele viitavaid kliinilisi sümptomeid. Selles grupis moodustus 2 alagruppi 
vastavalt rakendatud uuringumetoodikale. Esimese alagrupi moodustasid rasv-
hapete oksüdatsiooni defektide kahtlusega patsiendid perioodil 2004–2007, 
keda testiti HADHA geeni põhimutatsiooni esinemise suhtes. Sellesse alagruppi 
kuulus 102 patsienti, kes olid suunatud kahest regionaalhaiglast Eestis (SA 
TÜK Lastekliinik ja SA Tallinna Lastehaigla). Teise alagrupi moodustasid 
sümptomaatilised patsiendid perioodil 2008–2011, kellel teostati plasma atsüül-
karnitiinide analüüs. Uuringusse suunamise näidustused olid ühtsed ja välja 
töötatud kirjanduse alusel – Duran jt., 2003. Sellesse alagruppi kuulus 496 
patsienti, kes olid samuti suunatud kahest regionaalhaiglast.  
 2003.–2009. aastal hinnati mitokondriaalsete haiguste esinemist hinnati 
kõigil patsientidel, kes olid hospitaliseeritud uuringuteks kahe regionaalhaigla 
vastsündinute ja lasteneuroloogia osakondadesse. Rutiinselt määrati kõigil mito-
kondriaalsele haigusele viitavate sümptomitega patsientidel seerumi laktaadi 
sisaldus. Referentsväärtusest kõrgema laktaadisisalduse esinemisel teostati 
täiendavad metaboolsed ja instrumentaalsed uuringud. Juhul, kui biokeemilised 
ja instrumentaalsed uuringud toetasid  mitokondriaalse haiguse võimalikku 
esinemist patsiendil, teostati diagnoosi täpsustamiseks lihasbiopsia iseloomulike 
patomorfoloogiliste muutuste tuvastamiseks ning vajadusel biokeemilisteks ja 
molekulaargeneetilisteks uuringuteks lihaskoest.   
 HADHA geeni molekulaargeneetilisel analüüsil rakendati 1) põhimutatsiooni 
otsest detekteerimist ja 2) geeni sekveneerimist. Plasma atsüülkarnitiine ana-
lüüsiti butüülestritena ning mõõdeti positiivse eellasiooni analüüsil. 
 
 
Tulemused ja arutelu 
1) Käesolevas töös rakendati kliinilisse praktikasse atsüülkarnitiinide analüüs, 
mis on kiire ja informatiivne meetod rasvhapete oksüdatsiooni defektide 
diagnostikas, võimaldades ühel analüüsil mitmete β-oksüdatsiooni mõjuta-
vate pärilike haiguste diagnostika. Selle meetodi kasutusele võtmine on 
olnud potensiaalselt elupäästev vähemalt 3 patsiendi jaoks, kes tuvastati 
antud uurimistöö käigus.  
2) Uuringus kasutatud kliinilised kriteeriumid atsüülkarnitiinide analüüsiks on 
praktilised ning sobivad rasvhapete oksüdatsiooni defektide selektiivseks 
skriininguks Eestis. 
a)  LCHAD defitsiit on kõige sagedamini esinev rasvhapete oksüdatsiooni 
defekt Eestis, esinemissagedusega 1:91,670 vastsündinu kohta. Hetero-
sügootne mutatsioon c.1528G>C HADHA geenil esineb sagedusega 
1:173 vastsündinu kohta – seega geenikandluse esinemine on võrreldav 
teiste Läänemere regiooni riikidega. 
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b) Selektiivse skriiningu tulemused toetavad Lilleväli jt., (2000) uuringu 
varasemat järeldust, et MCAD defitsiidi esinemissagedus Eestis on 
väiksem võrreldes teiste Euroopa riikidega.   
c) Antud uuringu käigus ei tuvastatud ühtegi teist rasvhapete oksüdatsiooni 
defekti ega karnitiini ainevahetushäiret. See on tõenäoliselt seotud Eesti 
väikesearvulise populatsiooni ja nende haiguste väga väikese esinemis-
sagedusega. 
3) Uuringu käigus tuvastati LCHAD defitsiidi esinemine kolmes perekonnas.  
a) Seitsmel HADHA alleelil kaheksast (87,5%) esines põhimutatsioon 
c.1528G>C.  
b) Ühel alleelil tuvastati ka üks varem kirjeldamata mutatsioon c.1690–
2A>G, mis põhjustab HADHA geeni ebanormaalse splaissingu ning on 
seotud LCHAD defitsiidi klassikalise kliinilise avaldumisega. 
c) LCHAD defitsiidi kliiniline avaldumine vastas haiguse raskeimatele 
avaldumisvormidele. See on iseloomulik mutatsiooni c.1528G>C homo-
sügootidele. Keskmine vanus esmasel sümptomite avaldumisel oli 7,1 
kuud (3,5–14 elukuud). Vähemalt kolmel patsiendil esines esmase epi-
soodi ajal hüpoglükeemia ning kahel neist oli hüpoglükeemiline episood 
fataalne.  
4) Kasutatud mitokondriaalsete haiguste diagnostika algoritm on informatiivne 
kõrgenenud vereseerumi laktaadi sisaldusega patsientidel. Kasutatud algo-
ritm võimaldab diagnoosida enamiku vastsündinu- ja imikueas avalduvaid 
haigusjuhte.  
5) Mitokondriaalsete haiguste esinemissagedus Eestis on 1:20,746 elussünni 
kohta. See korreleerub hästi mitokondriaalsete haiguste esinemissagedusega 
Rootsis ja Austraalias, toetades järeldust, et nende haiguste esinemine on 
sarnane erinevates populatsioonides. 
6) Töös on kirjeldatud haiguse kliinilist pilti kolmel hingamisahela kompleksi 
defitsiidiga patsiendil, kahel PDH defitsiidiga patsiendil ja ühel OTC defit-
siidiga patsiendil. Nende haigusjuhtude juures tahame rõhutada järgmist: 
a) Varem kirjeldamata c.17INS19bp mutatsioon SCO2 geeni teises eksonis 
tuvastati patsiendil, kellel esines hingamisahela IV kompleksi defitsiit. 
See mutatsioon põhjustab valgu sünteesi katkemise ning on seotud 
haigusvormidega, mis lõpevad surmaga varases eas. 
b) Patsientidel, kellel esineb homoplasmiline mutatsioon m.14674T>C mt-
tRNAGlu mitokondriaalses DNAs, esineb imikueas avalduv raske müo-
paatia, mis paraneb lapse kasvades. Siiski vajavad need patsiendid mito-
kondriaalset energia tootmist toetavat ravi.  
c) Mõlemal PDH defitsiidiga patsiendil tuvastati sarnane PDHA1 geno-
tüüp – heterosügootne mutatsioon c.904C>T. Kuigi ühel patsiendil 
(patsient 7) oli kliiniline kulg raskem, olid peamised kliinilised sümp-
toomid nagu ajuanomaaliad ja kasvupeetus kattuvad. 
d) Me kirjeldasime patsienti, kellel esines vaimne alaareng, epilepsia ja 
OTC aktiivsuse langusele viitavad sümptomid, kuid OTC geeni sekve-
neerimisel muutusi ei tuvastatud. Tsütogeneetilisel analüüsil ja moleku-
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laarsel karüotüpiseerimisel ilmnes X-kromosoomi lühikese õla deletsioon 
(Xp22.33-p.11.1). Inaktivatsiooni uuringutel tuvastati täielikult kallutatud 
X-kromosoomi inaktivatsioon. Tulemused võimaldavad järeldada, et X-
liitelise haiguse avaldumisel naissoost indiviidil mängivad rolli erinevad 
mehhanismid nagu suured deletsioonid X-kromosoomil, kallutatud X-
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